



Swaziland

Country Operational Plan

FY 2015



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

Agency	Funding Source			Funding Source	Applied Pipeline
	GAP	GHP-State	GHP-USAID	Total	
DOD		652,545		652,545	72,604
HHS/CDC	487,500	16,595,689		17,083,189	574,923
PC		1,054,048		1,054,048	0
State		120,000		120,000	428,945
State/AF		103,140		103,140	0
USAID		21,199,776	6,900,000	28,099,776	610,830
Total	487,500	40,853,961	6,900,000	47,112,698	1,687,302

Summary of Planned Funding by Budget Code and Agency

Budget Code	Agency						On Hold Amount	Total
	State	DOD	HHS/CDC	PC	State/AF	USAID		
CIRC	0	158,509	4,212			2,878,607	0	3,041,328
HBHC		57,901	1,531,593			1,469,515	0	3,059,009
HKID	140		0	798,483	103,140	3,748,394	0	4,650,157
HLAB		2,341	679,267			0	0	681,608
HMBL			85,000				0	85,000
HTXD						7,101,201	0	7,101,201
HTXS	116	81,976	8,561,619			6,351,843	0	14,995,554
HVAB	105			581		42,064	0	42,750
HVCT		27,440	1,153,150			123,903	0	1,304,493
HVMS	117,918	51,005	884,826	254,062		1,082,714	0	2,390,525
HVOP	192	27,534		444		2,223,923	0	2,252,093
HVSI	378	26,831	1,134,754			421,241	0	1,583,204
HVTB		126,985	1,140,204			331,572	0	1,598,761
MTCT			157,914			414,228	0	572,142
OHSS	1,151	92,023	402,527	478		1,074,422	0	1,570,601



PDCS			649,964			252,331	0	902,295
PDTX			698,159			583,818	0	1,281,977
	120,000	652,545	17,083,189	1,054,048	103,140	28,099,776	0	47,112,698



Technical Areas

Technical Area Summary

Technical Area: Care

Budget Code	Budget Code Planned Amount	On Hold Amount
HBHC	3,009,330	0
HKID	3,797,974	0
HVTB	1,494,884	0
PDCS	868,063	0
Total Technical Area Planned Funding:	9,170,251	0

Technical Area: Governance and Systems

Budget Code	Budget Code Planned Amount	On Hold Amount
HLAB	662,423	0
HVSI	1,400,000	0
OHSS	1,342,500	0
Total Technical Area Planned Funding:	3,404,923	0

Technical Area: Prevention

Budget Code	Budget Code Planned Amount	On Hold Amount
CIRC	2,986,703	0
HMBL	85,000	0
HVAB	0	0
HVCT	1,241,328	0
HVOP	2,186,684	0
MTCT	494,024	0
Total Technical Area Planned Funding:	6,993,739	0



Technical Area: Treatment

Budget Code	Budget Code Planned Amount	On Hold Amount
HTXD	7,083,174	0
HTXS	14,383,134	0
PDTX	1,169,579	0
Total Technical Area Planned Funding:	22,635,887	0

Technical Area Summary Indicators and Targets

Indicator Number	Label	2015	2016
PMTCT_STAT_DSD	PMTCT_STAT_DSD Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (DSD)	100 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	11	26,137
	Number of new ANC and L&D clients	11	27,444
	By: Known positives at entry	11	10,450
	By: Number of new positives identified	0	3,979
	Sum of Positives Status disaggregates	11	14,429
	Required only for DREAMS Countries - By Number of new positives: <15		
	Required only for DREAMS Countries - By Number of new positives: 15-19		
	Required only for DREAMS Countries - By Number of new positives: 20-24		
	Required only for DREAMS Countries - By Number of new positives: 25+		22

	Required only for DREAMS Countries - By Number of known positives: <15		
	Required only for DREAMS Countries - By Number of known positives: 15-19		
	Required only for DREAMS Countries - By Number of known positives: 20-24		
	Required only for DREAMS Countries - By Number of known positives: 25+		
	Required only for DREAMS Countries - Denominator: <15		
	Required only for DREAMS Countries - Denominator: <15-19		
	Required only for DREAMS Countries - Denominator: 20-24		
	Required only for DREAMS Countries - Denominator: 25+		22
PMTCT_STAT_TA	PMTCT_STAT_TA Number and percentage of pregnant women with known status (includes women who were tested for HIV and received their results) (TA)	98 %	
	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,860	2,731

	Number of new ANC and L&D clients	28,313	2,866
	By: Known positives at entry	5,573	829
	By: Number of new positives identified	4,923	264
	Sum of Positives Status disaggregates	10,496	1,093
	Required only for DREAMS countries - By known positives: <15		
	Required only for DREAMS countries - By known positives: 15-19		
	Required only for DREAMS countries - By known positives: 20-24		
	Required only for DREAMS countries - By known positives: 25+		
	Required only for DREAMS countries - By new positives: <15		
	Required only for DREAMS countries - By new positives: 15-19		
	Required only for DREAMS countries - By new positives: 20-24		
	Required only for DREAMS countries - By new positives: 25+		
	Required only for DREAMS countries - Denominator: <15		
	Required only for DREAMS countries - Denominator:		

	15-19		
	Required only for DREAMS countries - Denominator: 20-24		
	Required only for DREAMS countries - Denominator: 25+		
PMTCT_ARV_DSD	PMTCT_ARV_DSD Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (DSD)	100 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	11	8,670
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	11	9,860
	Life-long ART (including Option B+)	11	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	4,192
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	4,464

	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	11	0
	Sum of New and Current disaggregates	0	8,656
PMTCT_ARV_TA	PMTCT_ARV_TA Percentage of HIV-positive pregnant women who received antiretrovirals to reduce risk for mother-to-child-transmission (MTCT) during pregnancy and delivery (TA)	90 %	
	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,451	918
	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,496	1,009

	Life-long ART (including Option B+)	9,451	
	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	6,776	408
	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,675	511
	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
	Single-dose nevirapine (with or without tail)	0	0
	Sum of Regimen Type disaggregates	9,451	0
	Sum of New and Current disaggregates	9,451	919
PMTCT_FO_DSD	PMTCT_FO_DSD Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		6,792
	Number of HIV-exposed infants registered in the birth		8,204

	cohort at any time between 0 and 18 months of age (including transfer-ins)		
	HIV-infected: Linked to ART		237
	HIV-infected: Not linked to ART		30
	HIV-infected: Unknown link		
	HIV-uninfected: Not breastfeeding		1,168
	HIV-uninfected: Still breastfeeding		1,304
	HIV-uninfected: Breastfeeding status unknown		415
	Other: In care but no test done		113
	Other: Lost to follow-up		550
	Other: Died		76
	Other: Transferred out		96
PMTCT_FO_TA	PMTCT_FO_TA Final outcomes among HIV exposed infants registered in the birth cohort	n/a	
	Number of HIV-exposed infants with a documented outcome by 18 months of age disaggregated by outcome type.		910
	Number of HIV-exposed infants registered in the birth cohort at any time between 0 and 18 months of age (including transfer-ins)		1,026
	HIV-infected: Linked to ART		47

	HIV-infected: Not linked to ART		4
	HIV-infected: Unknown link		
	HIV-uninfected: Breastfeeding status unknown		135
	HIV-uninfected: Not breastfeeding		465
	HIV-uninfected: Still breastfeeding		568
	Other: Died		11
	Other: In care but no test done		98
	Other: Lost to follow-up		243
	Other: Transferred out		34
VMMC_AE_DSD	Number of males circumcised surgically or by medical device that experienced at least one moderate or severe adverse event(s) (AEs)		868
	By AE type: Number of VMMC clients with one or more moderate or severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical intra-operative AE(s), but no severe surgical intra-operative AE(s)		
	Sub-Disag: Surgical intra-operative AE(s) by		

	maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more moderate surgical post-operative AE(s), but no severe surgical post-operative AE(s)		
	Sub-Disag: By Surgical post-operative AE(s) by maximum severity category: Number of clients with one or more severe surgical intra-operative AE(s)		
	By AE Type: Number of VMMC clients with one or more moderate or severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by maximum severity category: Number of clients with one or more moderate medical device-related AE(s), but no severe medical device-related AE(s)		
	Sub-Disag: By Medical device-based AE(s) by		

	maximum severity category: Number of clients with one or more severe medical device-related AE(s)		
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	13,464	15,300
	By Age: <1		0
	By Age: 1-9	0	0
	By Age: 10-14		4,129
	By Age: 15-19		6,904
	By Age: 20-24		2,166
	By Age: 25-29		1,347
	By Age: 30-49		754
	By Age: 50+	0	0
	Sum of age disaggregates	790	13,199
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	133	662
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	11,600	10,964
	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	1,566	3,674
	By circumcision technique: Surgical VMMC	13,060	14,580
By circumcision technique:	2,240	720	

	Device-based VMMC		
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	12,799	14,580
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	261	0
VMMC_CIRC_TA	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	0	
	By Age: <1	0	
	By Age: 1-9	0	
	By Age: 10-14	0	
	By Age: 15-19	0	
	By Age: 20-24	0	
	By Age: 25-29		
	By Age: 30-49		
	By Age: 50+	0	
	Sum of Age disaggregations	0	
	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	0	
	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	0	

	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	0	
	By circumcision technique: Surgical VMMC	0	
	By circumcision technique: Device-based VMMC	0	
	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	0	
	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	
PrEP_NEW_DSD	PrEP_NEW_DSD Number of adult women and adolescent girls newly enrolled on oral or topical PrEP	n/a	
	Number of adult women and adolescent giRls newly enrolled on oral or topical PrEP		
	Estimated number of adolescent girls and young women (ages 15-24) in a district who are HIV uninfected and at elevated risk of HIV infection, as evidence by program or other data		

	Numerator: Female 15-19		
	Numerator: Female 20-24		259
	Denominator: Female 15-19		750
	Denominator: Female 20-24		1,876
PP_PREV_DSD	PP_PREV_DSD Percentage of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period (DSD)	35 %	
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	62,520	81,406
	Total number of people in the target population	177,563	707,814
	Age/sex: 10-14 Male		1,092
	Age/sex: 15-19 Male		5,156
	Age/sex: 20-24 Male		4,370
	Age/sex: 25-49 Male		14,058
	Age/sex: 50+ Male		98
	Age/sex: 10-14 Female		15,507
	Age/sex: 15-19 Female		20,063
	Age/sex: 20-24 Female		16,811
	Age/sex: 25-49 Female		15,362
	Age/sex: 50+ Female		11
	Sum of Age/Sex disaggregates		92,528
	PP_PREV_TA	PP_PREV_TA Percentage of the target population who completed a standardized	n/a

	HIV prevention intervention including the minimum components during the reporting period (TA-only)		
	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	0	
	Total number of people in the target population	0	
	Age/sex: 10-14 Male	0	
	Age/sex: 15-19 Male	0	
	Age/sex: 20-24 Male	0	
	Age/sex: 25-49 Male	0	
	Age/sex: 50+ Male	0	
	Age/sex: 10-14 Female	0	
	Age/sex: 15-19 Female	0	
	Age/sex: 20-24 Female	0	
	Age/sex: 25-49 Female	0	
	Age/sex: 50+ Female	0	
	Sum of Age/Sex disaggregates	0	
KP_PREV_DSD	KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD)	n/a	
	Number of key populations reached with individual	378	3,636

	and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required		
	Total estimated number of key population in the catchment area		10,707
	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	243	2,600
	By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	0
	By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum	0	0

	standards required)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	135	777
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	0	
	By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)		8,762
	By key population type: Males who inject drugs (Male PWID) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Females who inject drugs (Female PWID)		

	(Denominator: Total estimated number of key population in the catchment area)		
	By key population type: Men who have sex with men/Transgender (MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
	By key population type: MSM/TG who are male sex workers (subset MSM/TG) (Denominator: Total estimated number of key population in the catchment area)		
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	164,953	288,760
	By Test Result: Negative	143,167	247,329
	By Test Result: Positive	21,786	32,559
	Sum of Test Result disaggregates	164,953	279,888
	Test Result by Age and Sex: Positive: <1 Male		93
	Test Result by Age and Sex: Positive: 1-4 Male		404
	Test Result by Age and Sex: Positive: 5-9 Male		458
	Test Result by Age and Sex: Positive: 10-14 Male		635



	Test Result by Age and Sex: Positive: 15-19 Male		1,333
	Test Result by Age and Sex: Positive: 20-24 Male		2,157
	Test Result by Age and Sex: Positive: 25-49 Male		6,667
	Test Result by Age and Sex: Positive: 50+ Male		770
	Test Result by Age and Sex: Positive: <1 Female		89
	Test Result by Age and Sex: Positive: 1-4 Female		793
	Test Result by Age and Sex: Positive: 5-9 Female		501
	Test Result by Age and Sex: Positive: 10-14 Female		768
	Test Result by Age and Sex: Positive: 15-19 Female		2,668
	Test Result by Age and Sex: Positive: 20-24 Female		4,566
	Test Result by Age and Sex: Positive: 25-49 Female		8,249
	Test Result by Age and Sex: Positive: 50+ Female		938
	Test Result by Age and Sex: Negative: <1 Male		1,802
	Test Result by Age and Sex: Negative: 1-4 Male		6,167
	Test Result by Age and Sex: Negative: 5-9 Male		6,329
	Test Result by Age and Sex: Negative: 10-14 Male		10,864
	Test Result by Age and Sex: Negative: 15-19 Male		21,062

	Test Result by Age and Sex: Negative: 20-24 Male		25,256
	Test Result by Age and Sex: Negative: 25-49 Male		52,943
	Test Result by Age and Sex: Negative: 50+ Male		7,080
	Test Result by Age and Sex: Negative: <1 Female		1,820
	Test Result by Age and Sex: Negative: 1-4 Female		10,703
	Test Result by Age and Sex: Negative: 5-9 Female		5,065
	Test Result by Age and Sex: Negative: 10-14 Female		6,151
	Test Result by Age and Sex: Negative: 15-19 Female		21,624
	Test Result by Age and Sex: Negative: 20-24 Female		30,059
	Test Result by Age and Sex: Negative: 25-49 Female		40,925
	Test Result by Age and Sex: Negative: 50+ Female		9,820
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	27,931	22,153
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	51,471	108,628
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	12,487	24,711
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	73,064	116,233

	Sum of Aggregated Age/Sex <15	40,418	46,864
	Sum of Aggregated Age/Sex 15+	124,535	224,861
	Sum of Aggregated Age/Sex disaggregates	164,953	271,725
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		1,548
	Service Delivery Point by Result: Antenatal Clinic - Negative		10,890
	Service Delivery Point by Result: Labor & delivery - All results		575
	Service Delivery Point by Result: Labor & delivery - Positive		61
	Service Delivery Point by Result: Labor & delivery - Negative		514
	Service Delivery Point by Result: Under 5 Clinic – All results		5,903
	Service Delivery Point by Result: Under 5 Clinic - Positive		583
	Service Delivery Point by Result: Under 5 Clinic - Negative		5,320
	Service Delivery Point by Result: Maternal and Child		11,296

	Health Clinic – All Results		
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		1,099
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		10,197
	Service Delivery Point by Result: Tuberculosis – All results		1,302
	Service Delivery Point by Result: Tuberculosis - Positive		236
	Service Delivery Point by Result: Tuberculosis - Negative		1,066
	Service Delivery Point by Result: Sexually Transmitted Infections – All Results		19
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		0
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		19
	Service Delivery Point by Result: Outpatient Department – All Results		48,772
	Service Delivery Point by Result: Outpatient Department - Positive		6,553
	Service Delivery Point by Result: Outpatient Department - Negative		42,219
	Service Delivery Point by		2,196

	Result: Inpatient – All Results		
	Service Delivery Point by Result: Inpatient - Positive		306
	Service Delivery Point by Result: Inpatient - Negative		1,890
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		0
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		0
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All Results		14,026
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		598
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		13,428
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		1,303
	Service Delivery Point by Result: Voluntary Counseling		8,141

	& Testing (co-located) - Negative		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Positive		1,608
	Service Delivery Point by Result: Voluntary Counseling & Testing (stand alone) – Negative		14,387
	Service Delivery Point by Result: Mobile – All Results		85,362
	Service Delivery Point by Result: Mobile - Positive		9,492
	Service Delivery Point by Result: Mobile - Negative		74,599
	Service Delivery Point by Result: Home-based – All Results		20,000
	Service Delivery Point by Result: Home-based - Positive		2,017
	Service Delivery Point by Result: Home-based - Negative		17,983
	Service Delivery Point by Result: Other – All Results		139
	Service Delivery Point by Result: Other - Positive		22
	Service Delivery Point by Result: Other - Negative		117

HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	110,524	4,283
	By Test Result: Negative	90,861	3,194
	By Test Result: Positive	19,663	532
	Sum of Test Result disaggregates	110,524	3,726
	Test Result by Age and Sex: Positive: <1 Male		3
	Test Result by Age and Sex: Positive: 1-4 Male		9
	Test Result by Age and Sex: Positive: 5-9 Male		9
	Test Result by Age and Sex: Positive: 10-14 Male		8
	Test Result by Age and Sex: Positive: 15-19 Male		9
	Test Result by Age and Sex: Positive: 20-24 Male		32
	Test Result by Age and Sex: Positive: 25-49 Male		
	Test Result by Age and Sex: Positive: 50+ Male		25
	Test Result by Age and Sex: Positive: <1 Female		3
	Test Result by Age and Sex: Positive: 1-4 Female		19
	Test Result by Age and Sex: Positive: 5-9 Female		8
	Test Result by Age and Sex: Positive: 10-14 Female		9
	Test Result by Age and Sex:		27



	Positive: 15-19 Female		
	Test Result by Age and Sex: Positive: 20-24 Female		102
	Test Result by Age and Sex: Positive: 25-49 Female		518
	Test Result by Age and Sex: Positive: 50+ Female		14
	Test Result by Age and Sex: Negative: <1 Male		87
	Test Result by Age and Sex: Negative: 1-4 Male		184
	Test Result by Age and Sex: Negative: 5-9 Male		103
	Test Result by Age and Sex: Negative: 10-14 Male		99
	Test Result by Age and Sex: Negative: 15-19 Male		150
	Test Result by Age and Sex: Negative: 20-24 Male		340
	Test Result by Age and Sex: Negative: 25-49 Male		897
	Test Result by Age and Sex: Negative: 50+ Male		183
	Test Result by Age and Sex: Negative: <1 Female		87
	Test Result by Age and Sex: Negative: 1-4 Female		409
	Test Result by Age and Sex: Negative: 5-9 Female		111
	Test Result by Age and Sex: Negative: 10-14 Female		113
	Test Result by Age and Sex: Negative: 15-19 Female		359
	Test Result by Age and Sex:		675

	Negative: 20-24 Female		
	Test Result by Age and Sex: Negative: 25-49 Female		1,082
	Test Result by Age and Sex: Negative: 50+ Female		179
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,842	393
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,244	1,621
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,907	607
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	75,531	1,664
	Sum of Aggregated Age/Sex <15	13,749	1,000
	Sum of Aggregated Age/Sex 15+	96,775	3,285
	Sum of Aggregated Age/Sex disaggregates	110,524	4,285
	Service Delivery Point by Result: Antenatal Clinic - All results		
	Service Delivery Point by Result: Antenatal Clinic - Positive		42
	Service Delivery Point by Result: Antenatal Clinic - Negative		282
	Service Delivery Point by Result: Labor & delivery - All results		12

	Service Delivery Point by Result: Labor & delivery - Positive		2
	Service Delivery Point by Result: Labor & delivery - Negative		10
	Service Delivery Point by Result: Under 5 Clinic – All results		162
	Service Delivery Point by Result: Under 5 Clinic - Positive		12
	Service Delivery Point by Result: Under 5 Clinic - Negative		146
	Service Delivery Point by Result: Maternal and Child Health Clinic – All Results		281
	Service Delivery Point by Result: Maternal and Child Health Clinic - Positive		25
	Service Delivery Point by Result: Maternal and Child Health Clinic - Negative		256
	Service Delivery Point by Result: Tuberculosis – All results		30
	Service Delivery Point by Result: Tuberculosis - Positive		5
	Service Delivery Point by Result: Tuberculosis - Negative		25
	Service Delivery Point by Result: Sexually Transmitted		0

	Infections – All Results		
	Service Delivery Point by Result: Sexually Transmitted Infections - Positive		0
	Service Delivery Point by Result: Sexually Transmitted Infections - Negative		0
	Service Delivery Point by Result: Outpatient Department – All Results		1,204
	Service Delivery Point by Result: Outpatient Department - Positive		184
	Service Delivery Point by Result: Outpatient Department - Negative		1,020
	Service Delivery Point by Result: Inpatient – All Results		43
	Service Delivery Point by Result: Inpatient - Positive		7
	Service Delivery Point by Result: Inpatient - Negative		36
	Service Delivery Point by Result: HIV care and treatment clinic – All Results		0
	Service Delivery Point by Result: HIV care and treatment clinic - Positive		0
	Service Delivery Point by Result: HIV care and treatment clinic - Negative		0
	Service Delivery Point by Result: Voluntary Medical Male Circumcision – All		41

	Results		
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Positive		2
	Service Delivery Point by Result: Voluntary Medical Male Circumcision - Negative		39
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) – All Results		
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Positive		38
	Service Delivery Point by Result: Voluntary Counseling & Testing (co-located) - Negative		219
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - All		
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Positive		0
	Service Delivery Point by Result: Voluntary Counseling & Testing (standalone) - Negative		0
	Service Delivery Point by Result: Mobile – All Results		160
	Service Delivery Point by Result: Mobile - Positive		13
	Service Delivery Point by		147

	Result: Mobile - Negative		
	Service Delivery Point by Result: Home-based – All Results		0
	Service Delivery Point by Result: Home-based - Positive		0
	Service Delivery Point by Result: Home-based - Negative		0
	Service Delivery Point by Result: Other – All Results		3
	Service Delivery Point by Result: Other - Positive		0
	Service Delivery Point by Result: Other - Negative		3
	Test Result by Aggregated Age and Sex: Negative <15 Male		
	Test Result by Aggregated Age and Sex: Negative 15+ Male		671
	Test Result by Aggregated Age and Sex: Negative <15 Female		482
	Test Result by Aggregated Age and Sex: Negative 15+ Female		899
	Test Result by Aggregated Age and Sex: Positive <15 Male		24
	Test Result by Aggregated Age and Sex: Positive 15+ Male		94
	Test Result by Aggregated		33

	Age and Sex: Positive <15 Female		
	Test Result by Aggregated Age and Sex: Positive 15+ Female		121
TB_STAT_DSD	TB_STAT_DSD Percentage of registered new and relapsed TB cases with documented HIV status.	n/a	
	Number of registered new and relapsed TB cases with documented HIV status, during the reporting period.		6,024
	Total number of registered new and relapsed TB cases, during the reporting period.		6,307
	Sex: Male		3,147
	Sex: Female		2,877
	Age: <1		104
	Age: 1-4		274
	Age: 5-9		182
	Age: 10-14		243
	Age 15-19		
	Age: 20+		4,822
	Status: Positive		4,405
	Status: Negative		1,609
	TB_STAT_TA	TB_STAT_TA Percentage of registered new and relapsed TB cases with documented HIV status.	n/a
Number of registered new and relapsed TB cases with			123

	documented HIV status, during the reporting period.		
	Total number of registered new and relapsed TB cases, during the reporting period.		129
	Age 15-19		
	Age: <1		3
	Age: 1-4		4
	Age: 10-14		4
	Age: 20+		100
	Age: 5-9		3
	Sex: Female		58
	Sex: Male		65
	Status: Negative		32
	Status: Positive		91
GEND_GBVDSD	Number of people receiving post-GBV care	0	0
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-17 Male		0
	Age/Sex: 18-24 Male		0
	Age/Sex: 25+ Male		0
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		0
	Age/Sex: 15-17 Female		0
	Age/Sex: 18-24 Female		0
	Age/Sex: 25+ Female		0
	Sum of Age/Sex Disaggregates		0
	By type of service: Physical and/or Emotional Violence (Other Post-GBV Care)	0	
	By type of service: Sexual	0	

	Violence (Post-Rape Care)		
	By PEP service provision (related to sexual violence services provided)	0	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	41,155	18,512
	Age/Sex: <10 Male		0
	Age/Sex: 10-14 Male		0
	Age/Sex: 15-19 Male		16
	Age/Sex: 20-24 Male		347
	Age/Sex: 25+ Male		1,245
	Age/Sex: <10 Female		0
	Age/Sex: 10-14 Female		5,816
	Age/Sex: 15-19 Female		9,919
	Age/Sex: 20-24 Female		246
	Age/Sex: 25+ Female		918
	By Age: 0-9	0	
	By Age: 10-14	1,589	
	By Age: 15-19	7,556	
	By Age: 20-24	7,247	
	By Age: 25+	24,763	
	Sum of Age disaggregates	41,155	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	721	10,700
	Age/Sex: <1 Male		0
	Age/Sex: 1-4 Male		67
	Age/Sex: 5-9 Male		73
	Age/Sex: 10-14 Male		2,282

	Age/Sex: 15-17 Male		2,279
	Age/Sex: 18-24 Male		215
	Age/Sex: 25+ Male		292
	Age/Sex: <1 Female		0
	Age/Sex: 1-4 Female		64
	Age/Sex: 5-9 Female		68
	Age/Sex: 10-14 Female		2,410
	Age/Sex: 15-17 Female		2,412
	Age/Sex: 18+ Female		
	Age/Sex: 18-24 Female		230
	Age/Sex: 25+ Female		308
	Sum of Age/Sex disaggregates		10,700
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	32,080	54,184
	Age/Sex: <1 Male		3
	Age/Sex: 1-4 Male		163
	Age/Sex: 5-9 Male		163
	Age/Sex: 10-14 Male		10,181
	Age/Sex: 15-17 Male		8,045
	By: Age/sex: Male 18-24		2,551
	By: Age/sex: Male 25+		3,598
	Age/Sex: <1 Female		3
	Age/Sex: 1-4 Female		187
	Age/Sex: 5-9 Female		187
	Age/Sex: 10-14 Female		10,655
	Age/Sex: 15-17 Female		10,256
	By: Age/sex: 18-24 Female		3,791
	By: Age/sex: 25+ Female		4,346

	Sum of Age/Sex disaggregates		39,843
	Required only for DREAMS countries - By service, age and sex: Education Support Female <1		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Female 25+		
	Required only for DREAMS countries - By service, age and sex: Education Support Male <1		
	Required only for DREAMS		



	countries - By service, age and sex: Education Support Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Education Support Male 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 5-9		

	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver		



	Programs Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Female 18-24		
	Required only for DREAMS countries - By service, age		

	and sex: Social Protection Female 25+		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male <1		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 1-4		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 5-9		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 10-14		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 15-17		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 18-24		
	Required only for DREAMS countries - By service, age and sex: Social Protection Male 25+		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female <1		0
	Required only for DREAMS		0



	countries - By service, age and sex: Economic Strengthening Female 1-4		
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 5-9		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 10-14		149
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 15-17		648
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 18-24		655
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 25+		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male <1		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 1-4		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 5-9		0

	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 10-14		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 15-17		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24		0
	Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 25+		0
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	105,929	127,841
	Age/sex: <1 Male	0	565
	Age/sex: 1-4 Male	0	1,931
	Age/sex: 5-9 Male	0	2,310
	Age/sex: 10-14 Male	0	2,649
	Age/sex: 15-19 Male	0	2,440
	Age/sex: 20-24 Male	0	5,255
	Age/sex: 25-49 Male	0	26,658
	Age/sex: 50+ Male	0	7,136
	Age/sex: <1 Female	0	1,071
	Age/sex: 1-4 Female	0	1,948
	Age/sex: 5-9 Female	0	2,365

	Age/sex: 10-14 Female	0	2,631
	Age/sex: 15-19 Female	0	4,367
	Age/sex: 20-24 Female	0	12,408
	Age/sex: 25-49 Female	0	44,482
	Age/sex: 50+ Female	0	9,567
	Sun of Age/Sex disaggregates	0	127,783
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	1,172
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	15,883
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	1,186
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	31,893
	Sum of Aggregated Age/Sex disaggregates	0	50,134
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	2,711
	Age/sex: <1 Male	0	9
	Age/sex: 1-4 Male	0	37
	Age/sex: 5-9 Male	0	39
	Age/sex: 10-14 Male	0	37
	Age/sex: 15-19 Male	0	35
	Age/sex: 20-24 Male	0	86

	Age/sex: 25-49 Male	0	1,145
	Age/sex: 50+ Male	0	70
	Age/sex: <1 Female	0	38
	Age/sex: 1-4 Female	0	40
	Age/sex: 5-9 Female	0	42
	Age/sex: 10-14 Female	0	38
	Age/sex: 15-19 Female	0	69
	Age/sex: 20-24 Female	0	163
	Age/sex: 25-49 Female	0	414
	Age/sex: 50+ Female	0	69
	Sum of Age/Sex disaggregates	0	2,331
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	0	3
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	0	341
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	0	7
	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	0	317
	Sum of Aggregated Age/Sex disaggregates	0	668
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR	17,500	19,077

	viral load		
	Age/sex: <1 Male	0	137
	Age/sex: 1-4 Male	0	326
	Age/sex: 5-9 Male	0	375
	Age/sex: 10-14 Male	0	454
	Age/sex: 15-19 Male	0	436
	Age/sex: 20-24 Male	0	1,205
	Age/sex: 25-49 Male	0	3,954
	Age/sex: 50+ Male	0	809
	Age/sex: <1 Female	0	155
	Age/sex: 1-4 Female	0	314
	Age/sex: 5-9 Female	0	363
	Age/sex: 10-14 Female	0	412
	Age/sex: 15-19 Female	0	947
	Age/sex: 20-24 Female	0	2,705
	Age/sex: 25-49 Female	0	5,422
	Age/sex: 50+ Female	0	1,061
	Sum of Age/sex disaggregates	0	19,075
	Aggregated Age/sex: <15 Male	0	73
	Aggregated Age/sex: 15+ Male	0	1,005
	Aggregated Age/sex: <15 Female	0	63
	Aggregated Age/sex: 15+ Female	0	2,247
	Sum of Aggregated Age/sex disaggregates	0	3,388
CARE_NEW_TA	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period		341

	and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age/sex: <1 Female		7
	Age/sex: 1-4 Female		7
	Age/sex: 5-9 Female		7
	Age/sex: 10-14 Female		7
	Age/sex: 15-19 Female		17
	Age/sex: 20-24 Female		35
	Age/sex: 25-49 Female		77
	Age/sex: 50+ Female		11
	Age/sex: <1 Male		1
	Age/sex: 1-4 Male		6
	Age/sex: 5-9 Male		7
	Age/sex: 10-14 Male		7
	Age/sex: 15-19 Male		7
	Age/sex: 20-24 Male		20
	Age/sex: 25-49 Male		113
	Age/sex: 50+ Male		12
	Aggregated Age/sex: <15 Female		0
	Aggregated Age/sex: <15 Male		0
	Aggregated Age/sex: 15+ Female		33
	Aggregated Age/sex: 15+ Male		28
	Sum of Aggregated Age/sex disaggregates	0	3,388
	Sum of age/sex disaggregates		341

FN_THER_DSD	FN_THER_DSD Proportion of clinically undernourished PLHIV who received therapeutic or supplementary food	100 %	
	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	392	435
	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	392	435
	Age: <1	0	0
	Age: 1-4	0	16
	Age: 5-14	0	12
	Age: 15-17	0	22
	Age: 18+	0	385
	Sum of Age disaggregates	0	435
	Aggregated Age: <18	0	
	Aggregated Age: 18+	0	
	Sum of Aggregated Age disaggregates	0	
	By Pregnancy/Postpartum Status: Pregnant		
	By Pregnancy/Postpartum Status: Postpartum		
TB_IPT_DSD	TB_IPT_DSD Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly		32,179

	enrolled in HIV care who start IPT during the reporting period		
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		572
	Age: 1-4		1,465
	Age: 5-9		1,233
	Age: 10-14		1,540
	Age: 15-19		2,342
	Age: 20+		25,027
	Sum of Age disaggregates		32,179
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		1,150
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		11,099
	Sex: Male		12,380
	Sex: Female		19,799
TB_IPT_TA	TB_IPT_TA Proportion of PLHIV newly enrolled in HIV clinical care who start isoniazid preventive therapy (IPT)	n/a	
	The number of PLHIV newly enrolled in HIV care who start IPT during the reporting		258

	period		
	Number of HIV-positive adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
	Age: <1		4
	Age: 1-4		19
	Age: 5-9		16
	Age: 10-14		20
	Age: 15-19		37
	Age: 20+		162
	Sum of Age disaggregates		258
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: <15		4
	Age (Aggregated)- USE WITH HQ PERMISSION ONLY: 15+		64
	Sex: Male		128
	Sex: Female		130
FN_ASSESS_DSD	FN_ASSESS_DSD Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		91,120

	Number of HIV positive adults and children who received care and treatment services		88,271
	Age: <1		882
	Age: 1-4		3,705
	Age: 5-14		8,048
	Age: 15-17		4,217
	Age: 18+ years		74,267
	Sum of Age disaggregates		91,119
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		2,288
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		27,967
	By Pregnancy/Postpartum Status: Pregnant		22
	By Pregnancy/Postpartum Status: Postpartum		0
FN_ASSESS_TA	FN_ASSESS_TA Proportion of PLHIV who were nutritionally assessed via anthropometric measurement	n/a	
	The number of PLHIV who were nutritionally assessed via anthropometric measurement		6,496
	Number of HIV positive adults and children who received care and treatment services		8,166
	Age: <1		16

	Age: 1-4		114
	Age: 5-14		405
	Age: 15-17		239
	Age: 18+ years		5,722
	Sum of Age disaggregates		6,496
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY <18		447
	Age (Aggregated) - USE WITH HQ PERMISSION ONLY 18+		3,825
	By Pregnancy/Postpartum Status: Pregnant		0
	By Pregnancy/Postpartum Status: Postpartum		0
TB_ART_DSD	TB_ART_DSD Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	4,315	3,551
	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	0	4,800
	Age: <1		49
	Age: 1-4		145
	Age: 5-9		104

	Age: 10-14		152
	Age: 15-19		243
	Age: 20+		2,858
	Sum of Age disaggregates		3,551
	Male	0	1,887
	Female	0	1,663
	Sum of Sex disaggregates	0	3,550
	Newly tested	0	
	Known HIV-positive	0	1,121
	Sum of Test Status disaggregates	0	1,121
	Aggregated Age: <15	0	136
	Aggregated Age: 15+	0	1,282
	Sum of Aggregated Age disaggregates	0	1,418
	Timeliness: Art initiation <8 weeks of start of TB treatment		808
	Timeliness: Art initiation >8 weeks of start of TB treatment		1,157
TB_ART_TA	TB_ART_TA Percentage of HIV-positive new and relapsed registered TB cases on ART during TB treatment	n/a	
	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		73
	The number of registered new and relapse TB cases with documented		91

	HIV-positive status during TB treatment during the reporting period		
	Age: <1		0
	Age: 1-4		2
	Age: 5-9		1
	Age: 10-14		4
	Age: 15-19		4
	Age: 20+		62
	Sum of Age disaggregates		73
	Aggregated Age: <15		6
	Aggregated Age: 15+		55
	Sum of Aggregated Age disaggregates		61
	Male		39
	Female		34
	Sum of Sex disaggregates		73
	Known HIV-positive		18
	Newly tested		
	Sum of Test Status disaggregates		18
	Timeliness: Art initiation <8 weeks of start of TB treatment		14
	Timeliness: Art initiation >8 weeks of start of TB treatment		17
TB_OUTCOME_DSD	TB_OUTCOME_DSD TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB		3,782

	treatment among registered new and relapsed TB cases who are HIV-positive in the treatment cohort		
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		4,830
	Outcome by Age: Cured <1		16
	Outcome by Age: Cured 1-4		34
	Outcome by Age: Cured 5-9		23
	Outcome by Age: Cured 10-14		36
	Outcome by Age: Cured: 15-19		65
	Outcome by Age: Cured 20+		1,121
	Outcome by Age: Treatment Complete <1		14
	Outcome by Age: Treatment Complete 1-4		31
	Outcome by Age: Treatment Complete 5-9		19
	Outcome by Age: Treatment Complete 10-14		32
	Outcome by Age: Treatment Complete 15-19		61
	Outcome by Age: Treatment Complete 20+		1,071
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment		0



	Failed 5-9		
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		5
	Outcome by Age: Treatment Failed 20+		78
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		2
	Outcome by Age: Died 20+		127
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		4
	Outcome by Age: Lost to Follow-up 5-9		0
	Outcome by Age: Lost to Follow-up 10-14		4
	Outcome by Age: Lost to Follow-up 15-19		5
	Outcome by Age: Lost to Follow-up 20+		109
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 20+		0

	Evaluated 15-19		
	Outcome by Age: Not Evaluated 20+		21
	Outcome by Sex: Treatment Complete Female		
	Outcome by Sex: Treatment Complete Male		759
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Treatment failed Female		
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_OUTCOME_TA	TB_OUTCOME_TA TB treatment outcomes among registered new and relapsed TB cases who are HIV-positive	n/a	
	Aggregated outcomes of TB treatment among registered		39

	new and relapsed TB cases who are HIV-positive in the treatment cohort		
	The total number of registered new and relapsed TB cases who are HIV-positive registered in the treatment cohort		42
	Outcome by Age: Cured <1		0
	Outcome by Age: Cured 1-4		0
	Outcome by Age: Cured 5-9		0
	Outcome by Age: Cured 10-14		0
	Outcome by Age: Cured 15-19		0
	Outcome by Age: Cured 20+		18
	Outcome by Sex: Cured Female		
	Outcome by Sex: Cured Male		
	Outcome by Age: Treatment Complete <1		0
	Outcome by Age: Treatment Complete 1-4		0
	Outcome by Age: Treatment Complete 5-9		0
	Outcome by Age: Treatment Complete 10-14		0
	Outcome by Age: Treatment Complete 15-19		0
	Outcome by Age: Treatment Complete 20+		12
	Outcome by Sex: Treatment Complete Female		7



	Outcome by Sex: Treatment Complete Male		5
	Outcome by Age: Treatment Failed <1		0
	Outcome by Age: Treatment Failed 1-4		0
	Outcome by Age: Treatment Failed 5-9		0
	Outcome by Age: Treatment Failed 10-14		0
	Outcome by Age: Treatment Failed 15-19		0
	Outcome by Age: Treatment Failed 20+		0
	Outcome by Sex: Treatment Failed Female		
	Outcome by Sex: Treatment Failed Male		
	Outcome by Age: Died <1		0
	Outcome by Age: Died 1-4		0
	Outcome by Age: Died 5-9		0
	Outcome by Age: Died 10-14		0
	Outcome by Age: Died 15-19		0
	Outcome by Age: Died 20+		0
	Outcome by Sex: Died Female		
	Outcome by Sex: Died Male		
	Outcome by Age: Lost to Follow-up <1		0
	Outcome by Age: Lost to Follow-up 1-4		0
	Outcome by Age: Lost to Follow-up 5-9		0
	Outcome by Age: Lost to		0

	Follow-up 10-14		
	Outcome by Age: Lost to Follow-up 15-19		0
	Outcome by Age: Lost to Follow-up 20+		0
	Outcome by Sex: Lost to Follow-up Female		
	Outcome by Sex: Lost to Follow-up Male		
	Outcome by Age: Not Evaluated <1		0
	Outcome by Age: Not Evaluated 1-4		0
	Outcome by Age: Not Evaluated 5-9		0
	Outcome by Age: Not Evaluated 10-14		0
	Outcome by Age: Not Evaluated 15-19		0
	Outcome by Age: Not Evaluated 20+		0
	Outcome by Sex: Not Evaluated Female		
	Outcome by Sex: Not Evaluated Male		
TB_SCREEN_DSD	TB_SCREEN_DSD Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	72 %	
	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility	75,945	127,145

	during the reporting period		
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	105,929	127,841
	Age: <1	1,487	874
	Age: 1-4	2,029	3,554
	Age: 5-9	1,393	4,608
	Age: 10-14	1,263	4,940
	Age: 15-19	1,813	6,377
	Age: 20+		115,274
	Sum of Age disaggregates	7,985	135,627
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	6,171	2,954
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	69,774	43,415
	Sum of Aggregated Age disaggregates	75,945	46,369
	Sex: Male	28,455	45,329
	Sex: Female	47,490	92,457
	Sum of Sex disaggregates	75,945	137,786
TB_SCREEN_TA	TB_SCREEN_TA Percentage of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period.	n/a	
	The number of PLHIV who were screened for TB		1,539

	symptoms at the last clinical visit to an HIV care facility during the reporting period		
	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	0	2,711
	Age: <1		17
	Age: 1-4		69
	Age: 5-9		88
	Age: 10-14		85
	Age: 15-19		131
	Age: 20+		1,157
	Sum of Age disaggregates		1,547
	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15		18
	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+		244
	Sum of Aggregated Age disaggregates		262
	Sex: Female		930
	Sex: Male		644
	Sum of Sex disaggregates		1,574
PMTCT_EID_DSD	PMTCT_EID_DSD Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (DSD)	97 %	

	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	10,187	9,339
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	10,496	
	By infants who received a virologic test within 2 months of birth	9,168	8,546
	By infants who received their first virologic HIV test between 2 and 12 months of age	1,019	838
	Sum of Infant Age disaggregates	10,187	9,384
	By infants with a positive virologic test result within 12 months of birth	408	
	Number of infants with a positive virological test result within 2 months of birth		223
	Number of infants with a positive virological test result within 12 months of birth		202
PMTCT_EID_TA	PMTCT_EID_TA Percent of infants born to HIV-positive women that receive a virological HIV test within 12 months of birth (TA)	n/a	
	Number of infants who had a virologic HIV test within 12 months of birth during the		1,022

	reporting period		
	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)		
	By infants who received a virologic test within 2 months of birth		928
	By infants who received their first virologic HIV test between 2 and 12 months of age		96
	Sum of Infant Age disaggregates		1,024
	By infants with a positive virologic test result within 12 months of birth		
	Number of infants with a positive virological test result within 2 months of birth		29
	Number of infants with a positive virological test result within 12 months of birth		6
PMTCT_CTX_DSD	PMTCT_CTX_DSD Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two		9,283

	months of birth within the reporting period		
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
PMTCT_CTX_TA	PMTCT_CTX_TA Percentage of infants born to HIV-positive pregnant women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth	n/a	
	Number of infants born to HIV-infected women who were started on cotrimoxazole (CTX) prophylaxis within two months of birth within the reporting period		1,014
	Number of HIV-positive pregnant women identified in the reporting period (include known HIV- positive at entry)		
CARE_COMM_DSD	Number of HIV-infected adults and children receiving care and support services outside of the health facility		20,105
	Age/Sex: <1 Male		158
	Age/Sex: 1-4 Male		541
	Age/Sex: 5-9 Male		614
	Age/Sex: 10-14 Male		937
	Age/Sex: 15-19 Male		907
	Age/Sex: 20-24 Male		597
	Age/Sex: 25-49 Male		2,908
	Age/Sex: 50+ Male		921

	Age/Sex: <1 Female		493
	Age/Sex: 1-4 Female		545
	Age/Sex: 5-9 Female		594
	Age/Sex: 10-14 Female		921
	Age/Sex: 15-19 Female		1,030
	Age/Sex: 20-24 Female		1,242
	Age/Sex: 25-49 Female		4,056
	Age/Sex: 50+ Female		1,054
	Number of HIV-infected adults and children receiving care and support services outside of the health facility		11,018
CARE_COMM_TA	Age/Sex: <1 Female		15
	Age/Sex: <1 Male		12
	Age/Sex: 1-4 Female		118
	Age/Sex: 1-4 Male		96
	Age/Sex: 10-14 Female		120
	Age/Sex: 10-14 Male		138
	Age/Sex: 15-19 Female		244
	Age/Sex: 15-19 Male		75
	Age/Sex: 20-24 Female		816
	Age/Sex: 20-24 Male		103
	Age/Sex: 25-49 Female		5,996
	Age/Sex: 25-49 Male		3,048
	Age/Sex: 5-9 Female		124
	Age/Sex: 5-9 Male		102
	Age/Sex: 50+ Female		1,080
	Age/Sex: 50+ Male		879
	TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	88,429
Age/Sex: <1 Male		0	446

	Age/Sex: 1-4 Male	0	1,941
	Age/Sex: 5-14 Male	0	4,359
	Age/Sex: 15-19 Male		3,045
	Age/Sex: 20+ Male		33,691
	Age/Sex: <1 Female	0	450
	Age/Sex: 1-4 Female	0	2,072
	Age/Sex: 5-14 Female	0	4,455
	Age/Sex: 15-19 Female		4,277
	Age/Sex: 20+ Female		59,413
	Aggregated Age/Sex: <1 Male	0	39
	Aggregated Age/Sex: <1 Female	0	36
	Aggregated Age/Sex: 15+ Male	0	13,678
	Aggregated Age/Sex: 1-14 Female		1,001
	Aggregated Age/Sex: 15+ Female	0	26,727
	Sum of Aggregated Age/Sex <15	0	
	Sum of Aggregated Age/Sex 15+	0	40,405
	Sum of Aggregated Age/Sex disaggregates	0	40,405
	Aggregated Age/Sex: 1-14 Male		958
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	2,034
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	11,160	1,341
	Age/Sex: <1 Male	0	8

	Age/Sex: 1-4 Male	0	31
	Age/Sex: 5-14 Male	0	66
	Age/Sex: 15-19 Male		31
	Age/Sex: 20+ Male		505
	Age/Sex: <1 Female	0	11
	Age/Sex: 1-4 Female	0	32
	Age/Sex: 5-14 Female	0	69
	Age/Sex: 15-19 Female		58
	Age/Sex: 20+ Female		530
	Sum of Age/Sex disaggregations	0	1,341
	Aggregated Age/Sex: <1 Male	0	0
	Aggregated Age/Sex: <1 Female	0	0
	Aggregated Age/Sex: 1-14 Male		2
	Aggregated Age/Sex: 15+ Male	0	271
	Aggregated Age/Sex: 1-14 Female		4
	Aggregated Age/Sex: 15+ Female	0	238
	Sum of Aggregated Age/Sex <15	0	
	Sum of Aggregated Age/Sex 15+	0	509
	Sum of Aggregated Age/Sex disaggregates	0	509
	Sum of Aggregated Age/Sex (<1 and 1-14) <15	0	6
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	14,000	20,079

	By Age/Sex: <1 Male	0	134
	By Age/Sex: 1-4 Male	0	412
	By Age/Sex: 5-9 Male	0	411
	By Age/Sex: 10-14 Male	0	478
	By Age/Sex: 15-19 Male	0	372
	By Age/Sex: 20-24 Male	0	932
	By Age/Sex: 25-49 Male	0	4,371
	By Age/Sex: 50+ Male	0	770
	By Age/Sex: <1 Female	0	134
	By Age/Sex: 1-4 Female	0	405
	By Age/Sex: 5-9 Female	0	397
	By Age/Sex: 10-14 Female	0	414
	By Age/Sex: 15-19 Female	0	936
	By Age/Sex: 20-24 Female	0	2,693
	By Age/Sex: 25-49 Female	0	6,114
	By Age/Sex: 50+ Female	0	1,106
	Sum of Age/Sex disaggregates	0	20,079
	Aggregated Grouping by Age: <1 Male	0	5
	Aggregated Grouping by Age/Sex: 1-14 Male		108
	Aggregated Grouping by Age/Sex: 15+ Male	0	1,656
	Aggregated Grouping by Age/Sex: <1 Female	0	4
	Aggregated Grouping by Age/Sex: 15+ Female	0	3,691
	Sum of Aggregated Age/Sex disaggregates	0	5,347
	Pregnancy status		2,980
	Breastfeeding status		334
	Aggregated Grouping by		94

	Age/Sex: 1-14 Female		
TX_NEW_TA	Number of adults and children newly enrolled on antiretroviral therapy (ART)		322
	By Age/Sex: <1 Male		1
	By Age/Sex: 1-4 Male		7
	By Age/Sex: 5-9 Male		7
	By Age/Sex: 10-14 Male		7
	By Age/Sex: 15-19 Male		7
	By Age/Sex: 20-24 Male		18
	By Age/Sex: 25-49 Male		112
	By Age/Sex: 50+ Male		10
	By Age/Sex: <1 Female		1
	By Age/Sex: 1-4 Female		7
	By Age/Sex: 5-9 Female		7
	By Age/Sex: 10-14 Female		7
	By Age/Sex: 15-19 Female		13
	By Age/Sex: 20-24 Female		32
	By Age/Sex: 25-49 Female		77
	By Age/Sex: 50+ Female		9
	Sum of Age/Sex disaggregates		322
	Aggregated Grouping by Age: <1 Male		0
	Aggregated Grouping by Age/Sex: 1-14 Male		0
Aggregated Grouping by Age/Sex: 15+ Male		76	
Aggregated Grouping by Age: <1 Female		0	
Aggregated Grouping by Age/Sex: 1-14 Female		0	
Aggregated Grouping by		61	

	Age/Sex: 15+ Female		
	Sum of Aggregated Age/Sex disaggregates		137
	Pregnancy status		37
	Breastfeeding status		6
TX_RET_DSD	TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	92 %	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,672	10,335
	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,507	11,742
	Age/Sex: <5 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		263
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		366
	Age/Sex: 15-19 Male		227

	(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		3,255
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		289
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		372
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		354
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		5,209
	Age/Sex: <5 Male		305

	(Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		422
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		266
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		3,670

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		329
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		427
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		414
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who		5,909

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Numerator by Status: Pregnant		9
	Numerator by Status: Breastfeeding		0
	Denominator by Status: Pregnant		0
	Denominator by Status: Breastfeeding		0
	TX_RET_TA Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy	n/a	
	Number of adults and children who are still alive and on treatment at 12 months after initiating ART		1,280
TX_RET_TA	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up		1,539
	Age/Sex: <5 Male (Numerator: Number of adults and children who are		36

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 5-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		48
	Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		15
	Age/Sex: 20+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		450
	Age/Sex: <5 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		41
	Age/Sex: 5-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		45
	Age/Sex: 15-19 Female (Numerator: Number of adults and children who are		28

	still alive and on treatment at 12 months after initiating ART)		
	Age/Sex: 20+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)		617
	Age/Sex: <5 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		47
	Age/Sex: 5-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		54
	Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have		16

	died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		549
	Age/Sex: <5 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		53
	Age/Sex: 5-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		46
	Age/Sex: 15-19 Female (Denominator: Total number of adults and children who		37

	initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		
	Age/Sex: 20+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)		737
	Numerator by Status: Pregnant		0
	Numerator by Status: Breastfeeding		0
	Denominator by Status: Pregnant		0
	Denominator by Status: Breastfeeding		0
TX_VIRAL_DSD	TX_VIRAL_DSD Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months		6,848
	Number of adults and		11,461

	children on ART at least 6 months whose medical records were reviewed		
	Age/Sex: <1 Male		35
	Age/Sex: 1-4 Male		319
	Age/Sex: 5-14 Male		433
	Age/Sex: 15-19 Male		449
	Age/Sex: 20+ Male		1,504
	Age/Sex: <1 Female		240
	Age/Sex: 1-4 Female		326
	Age/Sex: 5-14 Female		533
	Age/Sex: 15-19 Female		586
	Age/Sex: 20+ Female		2,421
	Results Category: Undetectable		5,839
	Results Category: Detectable		965
TX_VIRAL_TA	TX_VIRAL_TA Percentage of ART patients with an undetectable viral load at 12 months after initiation of ART	n/a	
	Number of adult and pediatric ART patients with a viral load result documented in the patient medical record within the past 12 months.		178
	Number of adults and children on ART at least 6 months whose medical records were reviewed.		323
	Age/Sex: <1 Male		1
	Age/Sex: 1-4 Male		10
	Age/Sex: 5-14 Male		14
	Age/Sex: 15-19 Male		18
	Age/Sex: 20+ Male		30

	Age/Sex: <1 Female		11
	Age/Ses: 1-4 Female		11
	Age/Sex: 5-14 Female		17
	Age/Sex: 15-19 Female		24
	Age/Sex: 20+ Female		42
	Result Category: Undetectable		118
	Result Category: Detectable		15
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8	2
LAB_ACC_TA	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation		7
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	150	98
	By clinical laboratories	14	58
	By Point-of-care testing sites	136	40

LAB_CAP_TA	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests		101
	By clinical laboratories		0
	By Point-of-care testing sites		116
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	100	
	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	150	482
	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	130	482
	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	130	482
	CD4: Number of laboratories that perform this testing	36	90
	CD4: Number of laboratories that participate in this PT program	36	90
	CD4: Number of laboratories that achieve acceptable	25	90

	successful passing criteria in this PT program		
	Early infant diagnostics: Number of laboratories that perform this testing	1	2
	Early infant diagnostics: Number of laboratories that participate in this PT program	1	2
	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	2
	HIV viral load: Number of laboratories that perform this testing	1	2
	HIV viral load: Number of laboratories that participate in this PT program	1	2
	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	2
	TB diagnostics (AFB microscopy): Number of laboratories that perform this testing		40
	TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program		40
	TB diagnostics (AFB microscopy): Number of		40

	laboratories that achieve acceptable successful passing criteria in this PT program		
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing		40
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program		40
	TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program		40
	TB diagnostics (Culture/DST): Number of laboratories that perform this testing		2
	TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program		2
	TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program		2
TX_UNDETECT_DSD	TX_UNDETECT_DSD Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	

	Number of viral load tests from adult and pediatric ART patients conducted in the past 12 months with a viral load <1,000 copies/ml		49,279
	Number of viral load tests performed from adults and children on ART within the current reporting period		54,750
	Age/Sex: <1 Male		769
	Age/Sex: 1-4 Male		1,914
	Age/Sex: 5-14 Male		3,347
	Age/Sex: 15-19 Male		3,617
	Age/Sex: 20+ Male		13,618
	Age/Sex: <1 Female		766
	Age/Sex: 1-4 Female		1,954
	Age/Sex: 5-14 Female		3,313
	Age/Sex: 15-19 Female		3,768
	Age/Sex: 20+ Female		16,205
	Pregnant		5
	Breastfeeding		89
	Test indication: Routine monitoring		1,390
	Test indication: Targeted monitoring		
TX_UNDETECT_TA	TX_UNDETECT_TA Proportion of viral load tests with an undetectable viral load (<1000 copies/ml)	n/a	
	Number of viral load tests from adult and pediatric ART patients conducted in the		1,765

	past 12 months with a viral load <1,000 copies/ml		
	Number of viral load tests performed from adults and children on ART within the current reporting period		1,962
	Age/Sex: <1 Female		47
	Age/Sex: <1 Male		46
	Age/Sex: 1-4 Female		104
	Age/Sex: 1-4 Male		104
	Age/Sex: 15-19 Female		193
	Age/Sex: 15-19 Male		190
	Age/Sex: 20+ Female		398
	Age/Sex: 20+ Male		356
	Age/Sex: 5-14 Female		164
	Age/Sex: 5-14 Male		163
	Breastfeeding		1
	Pregnant		0
	Test indication: Routine monitoring		
	Test indication: Targeted monitoring		0
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	275	563
	By Graduates: Doctors	1	0
	By Graduates: Nurses	186	218
	By Graduates: Midwives	64	165
	By Graduates: Social service	0	0

	workers		
	By Graduates: Laboratory professionals	0	26
	By Graduates: Other	24	106
	Sum of Graduates disaggreagtes	275	515
FPINT_SITE_DSD	FPINT_SITE_DSD Family Planning and HIV Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services	93 %	
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	137	120
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	147	122
	Service delivery type: Care and Support		41
	Service delivery type: Treatment		41
	Service delivery type: PMTCT		40
	Sum of Service delivery type (Care, Tx and PMTCT) disaggregates		
	FPINT_SITE_TA	FPINT_SITE_TA Family Planning and HIV	n/a

	Integration: Percentage of HIV service delivery points supported by PEPFAR that are directly providing integrated voluntary family planning services		
	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services		18
	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment		18
	Service delivery type: Care and Support		6
	Service delivery type: Treatment		6
	Service delivery type: PMTCT		6
	Sum of Service Delivery Type (Care, Tx and PMTCT) disaggregates		18

Partners and Implementing Mechanisms

Partner List

Mech ID	Partner Name	Organization Type	Agency	Funding Source	Planned Funding
10157	Pact, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	0
10247	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
10703	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	958,000
11673	U.S. Department of Defense (Defense)	Other USG Agency	U.S. Department of Defense	GHP-State	534,912
13144	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13630	Population Services International	NGO	U.S. Agency for International Development	GHP-State	0
13645	Elizabeth Glaser Pediatric AIDS	NGO	U.S. Agency for International	GHP-State	0

	Foundation		Development		
13738	Elizabeth Glaser Pediatric AIDS Foundation	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
13742	FHI 360	NGO	U.S. Agency for International Development	GHP-State, GHP-USAID	513,737
13791	Population Services International	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,028,842
14201	Mothers 2 Mothers	NGO	U.S. Agency for International Development	GHP-State	1,299,621
14374	Association of Public Health Laboratories	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	0
14842	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	51,570
16760	University Research Corporation, LLC	Private Contractor	U.S. Agency for International Development	GHP-USAID	0
16812	African Society for	NGO	U.S. Department	GAP, GHP-State	0

	Laboratory Medicine		of Health and Human Services/Centers for Disease Control and Prevention		
16815	Abt Associates	Private Contractor	U.S. Agency for International Development	GHP-State	600,000
16821	Johns Hopkins University Bloomberg School of Public Health	University	U.S. Agency for International Development	GHP-State	1,260,307
17096	United Nations Children's Fund	Multi-lateral Agency	U.S. Agency for International Development	GHP-State	0
17389	U.S. Peace Corps	Other USG Agency	U.S. Peace Corps	GHP-State	54,603
17454	Centre for HIV and AIDS Prevention Studies Swaziland	NGO	U.S. Agency for International Development	GHP-State	2,631,464
17455	U.S. Department of State	Other USG Agency	U.S. Department of State/Bureau of African Affairs	GHP-State	51,570
17458	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	1,200,000
17460	University Research Corporation, LLC	Private Contractor	U.S. Department of Health and Human	GHP-State	4,061,946

			Services/Centers for Disease Control and Prevention		
17461	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	2,756,640
17462	Ministry of Health-Swaziland	Host Country Government Agency	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	689,500
17463	International Center for AIDS Care and Treatment Programs, Columbia University	University	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	5,297,575
17464	Pact	Multi-lateral Agency	U.S. Agency for International Development	GHP-State, GHP-USAID	3,175,650
17465	John Snow, Inc.	Private Contractor	U.S. Agency for International Development	GHP-State	5,526,824
17548	Partnership for Supply Chain Management	Private Contractor	U.S. Agency for International Development	GHP-State, GHP-USAID	7,083,174
17555	VISTA PARTNERS	Implementing Agency	U.S. Department of Defense	GHP-State	26,831

17559	Regional Procurement Support Office/Frankfurt	Other USG Agency	U.S. Agency for International Development	GHP-State	0
17572	American Association of Blood Banks	NGO	U.S. Department of Health and Human Services/Centers for Disease Control and Prevention	GHP-State	85,000
17775	Management Sciences for Health	NGO	U.S. Agency for International Development	GHP-State	0
17965	TBD	TBD	Redacted	Redacted	Redacted
17966	Population Services International	NGO	U.S. Agency for International Development	GHP-State	645,742
17967	TBD	TBD	Redacted	Redacted	Redacted
17972	Measure Evaluation	NGO	U.S. Agency for International Development	GHP-State	936,169



Implementing Mechanism(s)

Implementing Mechanism Details

Mechanism ID: 10157	Mechanism Name: PACT
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Pact, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10157
Mechanism Name:	PACT
Prime Partner Name:	Pact, Inc.

Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	6,562	

PP_PREV_DSD	Total number of people in the target population	102,156	
PP_PREV_DSD	Age/sex: 10-14 Male	725	
PP_PREV_DSD	Age/sex: 15-19 Male	946	
PP_PREV_DSD	Age/sex: 20-24 Male	613	
PP_PREV_DSD	Age/sex: 25-49 Male	435	
PP_PREV_DSD	Age/sex: 50+ Male	167	
PP_PREV_DSD	Age/sex: 10-14 Female	881	
PP_PREV_DSD	Age/sex: 15-19 Female	1,075	
PP_PREV_DSD	Age/sex: 20-24 Female	671	
PP_PREV_DSD	Age/sex: 25-49 Female	753	
PP_PREV_DSD	Age/sex: 50+ Female	296	
PP_PREV_DSD	Sum of Age/Sex disaggregates	6,562	
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	1,156	
HTC_TST_DSD	By Test Result: Negative	1,034	
HTC_TST_DSD	By Test Result: Positive	122	
HTC_TST_DSD	Sum of Test Result disaggregates	1,156	
HTC_TST_DSD	Age/sex: <1 Male	0	
HTC_TST_DSD	Age/sex: 1-4 Male	13	
HTC_TST_DSD	Age/sex: 5-9 Male	35	
HTC_TST_DSD	Age/sex: 10-14 Male	41	
HTC_TST_DSD	Age/sex: 15-19 Male	34	
HTC_TST_DSD	Age/sex: 20-24 Male	36	
HTC_TST_DSD	Age/sex: 25-49 Male	207	
HTC_TST_DSD	Age/sex: 50+ Male	128	
HTC_TST_DSD	Age/sex: <1 Female	0	
HTC_TST_DSD	Age/sex: 1-4 Female	26	
HTC_TST_DSD	Age/sex: 5-9 Female	42	
HTC_TST_DSD	Age/sex: 10-14 Female	36	
HTC_TST_DSD	Age/sex: 15-19 Female	47	

HTC_TST_DSD	Age/sex: 20-24 Female	54	
HTC_TST_DSD	Age/sex: 25-49 Female	345	
HTC_TST_DSD	Age/sex: 50+ Female	112	
HTC_TST_DSD	Sum of Age/Sex disaggregates	1,156	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	89	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	406	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	103	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	558	
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	192	
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	964	
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	1,156	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	1,275	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	89	
GEND_NORM_DSD	By Age: 15-19	326	
GEND_NORM_DSD	By Age: 20-24	217	
GEND_NORM_DSD	By Age: 25+	643	
GEND_NORM_DSD	Sum of Age disaggregates	1,275	
GEND_NORM_DSD	By Sex: Male	480	
GEND_NORM_DSD	By Sex: Female	795	
GEND_NORM_DSD	Sum of Sex disaggregates	1,275	
GEND_NORM_DSD	By type of activity: Individual	588	
GEND_NORM_DSD	By type of activity: Small Group	688	
GEND_NORM_DSD	By type of activity: Community-level	0	
GEND_NORM_TA	Sum of Sex disaggregates	1,275	
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to	180	

	access HIV services		
OVC_ACC_DSD	Sex: Male	93	
OVC_ACC_DSD	Sex: Female	87	
OVC_ACC_DSD	Sum of Sex disaggregates	180	
OVC_ACC_DSD	Age: <1	0	
OVC_ACC_DSD	Age: 1-4	0	
OVC_ACC_DSD	Age: 5-9	8	
OVC_ACC_DSD	Age: 10-14	34	
OVC_ACC_DSD	Age: 15-17	83	
OVC_ACC_DSD	Age: 18+	55	
OVC_ACC_DSD	Sum of Age disaggregates	180	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	9,410	
OVC_SERV_DSD	Sex: Male	4,598	
OVC_SERV_DSD	Sex: Female	4,812	
OVC_SERV_DSD	Sum of Sex disaggregates	9,410	
OVC_SERV_DSD	Age: <1	34	
OVC_SERV_DSD	Age: 1-4	749	
OVC_SERV_DSD	Age: 5-9	1,145	
OVC_SERV_DSD	Age: 10-14	3,294	
OVC_SERV_DSD	Age: 15-17	2,894	
OVC_SERV_DSD	Age: 18+	1,294	
OVC_SERV_DSD	Sum of Age disaggregates	9,410	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,460	
CARE_CURR_DSD	Age/sex: <1 Male	0	
CARE_CURR_DSD	Age/sex: 1-4 Male	23	
CARE_CURR_DSD	Age/sex: 5-9 Male	125	
CARE_CURR_DSD	Age/sex: 10-14 Male	131	

CARE_CURR_DSD	Age/sex: 15-19 Male	40	
CARE_CURR_DSD	Age/sex: 20-24 Male	7	
CARE_CURR_DSD	Age/sex: 25-49 Male	381	
CARE_CURR_DSD	Age/sex: 50+ Male	194	
CARE_CURR_DSD	Age/sex: <1 Female	0	
CARE_CURR_DSD	Age/sex: 1-4 Female	56	
CARE_CURR_DSD	Age/sex: 5-9 Female	127	
CARE_CURR_DSD	Age/sex: 10-14 Female	102	
CARE_CURR_DSD	Age/sex: 15-19 Female	79	
CARE_CURR_DSD	Age/sex: 20-24 Female	92	
CARE_CURR_DSD	Age/sex: 25-49 Female	840	
CARE_CURR_DSD	Age/sex: 50+ Female	263	
CARE_CURR_DSD	Sun of Age/Sex disaggregates	2,460	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	279	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	621	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	286	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,274	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	2,460	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	138	
CARE_NEW_DSD	Age/sex: <1 Male	0	
CARE_NEW_DSD	Age/sex: 1-4 Male	1	
CARE_NEW_DSD	Age/sex: 5-9 Male	7	
CARE_NEW_DSD	Age/sex: 10-14 Male	8	
CARE_NEW_DSD	Age/sex: 15-19 Male	2	

CARE_NEW_DSD	Age/sex: 20-24 Male	1	
CARE_NEW_DSD	Age/sex: 25-49 Male	21	
CARE_NEW_DSD	Age/sex: 50+ Male	11	
CARE_NEW_DSD	Age/sex: <1 Female	0	
CARE_NEW_DSD	Age/sex: 1-4 Female	3	
CARE_NEW_DSD	Age/sex: 5-9 Female	7	
CARE_NEW_DSD	Age/sex: 10-14 Female	6	
CARE_NEW_DSD	Age/sex: 15-19 Female	4	
CARE_NEW_DSD	Age/sex: 20-24 Female	5	
CARE_NEW_DSD	Age/sex: 25-49 Female	47	
CARE_NEW_DSD	Age/sex: 50+ Female	15	
CARE_NEW_DSD	Sum of Age/sex disaggregates	138	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	16	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	35	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	16	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	71	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	138	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	138	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	140	
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	140	
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	5	
FN_THER_DSD	Age: 5-14	27	
FN_THER_DSD	Age: 15-17	6	
FN_THER_DSD	Age: 18+	102	
FN_THER_DSD	Sum of Age disaggregates	140	
FN_THER_DSD	Aggregated Age: <18	38	
FN_THER_DSD	Aggregated Age: 18+	102	

FN_THER_DSD	Sum of Aggregated Age disaggregates	140	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	68	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	68	
TB_ART_DSD	Age: 0-4	0	
TB_ART_DSD	Age: 5-14	6	
TB_ART_DSD	Age: 15+	62	
TB_ART_DSD	Male	34	
TB_ART_DSD	Female	34	
TB_ART_DSD	Sum of Sex disaggregates	68	
TB_ART_DSD	Newly tested	14	
TB_ART_DSD	Known HIV-positive	54	
TB_ART_DSD	Sum of Test Status disaggregates	68	
TB_ART_DSD	Aggregated Age: <15	6	
TB_ART_DSD	Aggregated Age: 15+	62	
TB_ART_DSD	Sum of Aggregated Age disaggregates	68	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	83	
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	83	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	83	
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	0	
PMTCT_EID_DSD	Sum of Infant Age disaggregates	83	
TX_CURR_DSD	Number of adults and children receiving	7,670	

	antiretroviral therapy (ART)		
TX_CURR_DSD	Age/Sex: <1 Male	80	
TX_CURR_DSD	Age/Sex: 1-4 Male	70	
TX_CURR_DSD	Age/Sex: 5-14 Male	780	
TX_CURR_DSD	Age/Sex: 15+ Male	1,889	
TX_CURR_DSD	Age/Sex: <1 Female	99	
TX_CURR_DSD	Age/Sex: 1-4 Female	170	
TX_CURR_DSD	Age/Sex: 5-14 Female	700	
TX_CURR_DSD	Age/Sex: 15+ Female	3,882	
TX_CURR_DSD	Sum of age/sex disaggregates	1,899	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	25	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	80	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	99	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	930	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	1,889	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	969	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	3,882	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,899	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	5,771	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	7,670	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	179	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	306	
TX_NEW_DSD	By Age/Sex: <1 Male	4	
TX_NEW_DSD	By Age/Sex: 1-4 Male	3	
TX_NEW_DSD	By Age/Sex: 5-9 Male	15	
TX_NEW_DSD	By Age/Sex: 10-14 Male	16	

TX_NEW_DSD	By Age/Sex: 15-19 Male	5	
TX_NEW_DSD	By Age/Sex: 20-24 Male	1	
TX_NEW_DSD	By Age/Sex: 25-49 Male	46	
TX_NEW_DSD	By Age/Sex: 50+ Male	24	
TX_NEW_DSD	By Age/Sex: <1 Female	5	
TX_NEW_DSD	By Age/Sex: 1-4 Female	7	
TX_NEW_DSD	By Age/Sex: 5-9 Female	16	
TX_NEW_DSD	By Age/Sex: 10-14 Female	12	
TX_NEW_DSD	By Age/Sex: 15-19 Female	9	
TX_NEW_DSD	By Age/Sex: 20-24 Female	11	
TX_NEW_DSD	By Age/Sex: 25-49 Female	101	
TX_NEW_DSD	By Age/Sex: 50+ Female	31	
TX_NEW_DSD	Sum of Age/Sex disaggregates	306	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	4	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	38	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	75	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	5	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	39	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	154	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	306	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	281	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	313	
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	

TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	28	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	276	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	34	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	248	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	38	

TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	276	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	0	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	0	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	2,460	
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,460	
TB_SCREEN_DSD	Age: <1	0	
TB_SCREEN_DSD	Age: 1-4	79	
TB_SCREEN_DSD	Age: 5-9	253	
TB_SCREEN_DSD	Age: 10-14	233	
TB_SCREEN_DSD	Age: 15-19	118	
TB_SCREEN_DSD	Age: 20-24	98	
TB_SCREEN_DSD	Age: 25-49	1,222	
TB_SCREEN_DSD	Age: 50+	457	
TB_SCREEN_DSD	Sum of Age disaggregates	683	



TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	565	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	1,895	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	2,460	
TB_SCREEN_DSD	Sex: Male	900	
TB_SCREEN_DSD	Sex: Female	1,560	
TB_SCREEN_DSD	Sum of Sex disaggregates	2,460	

Implementing Mechanism Details

Mechanism ID: 10247	Mechanism Name: ICAP/CDC: Improving Quality of Treatment Services
Funding Agency: HHS/CDC	Procurement Type: Contract
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10247		
Mechanism Name:	ICAP/CDC: Improving Quality of Treatment Services		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	84,377		Redacted
CARE_CURR_DS D	Age/sex: <1 Male	738		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	1,064		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	764		Redacted
CARE_CURR_DS	Age/sex: 10-14 Male	589		Redacted

D				
CARE_CURR_DS D	Age/sex: 15-19 Male	277		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	1,353		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	22,392		Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	4,442		Redacted
CARE_CURR_DS D	Age/sex: <1 Female	911		Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	1,191		Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	786		Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	810		Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	1,769		Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	7,346		Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	35,035		Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	4,910		Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	84,377		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	3,155		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,463		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,699		Redacted
CARE_CURR_DS	Aggregated Age/sex - USE WITH HQ	49,060		Redacted

D	PERMISSION ONLY: 15+ Female			
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	84,377		Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	10,228		Redacted
CARE_CURR_TA	Age/sex: <1 Male	91		Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	130		Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	94		Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	72		Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	35		Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	172		Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	2,840		Redacted
CARE_CURR_TA	Age/sex: 50+ Male	563		Redacted
CARE_CURR_TA	Age/sex: <1 Female	149		Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	196		Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	129		Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	132		Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	203		Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	842		Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	4,017		Redacted
CARE_CURR_TA	Age/sex: 50+ Female	563		Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	10,228		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	387		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	3,611		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	605		Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	5,625		Redacted



CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	10,228		Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	11,875		Redacted
CARE_NEW_DSD	Age/sex: <1 Male	135		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	195		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	140		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	108		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	40		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	203		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	3,348		Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	664		Redacted
CARE_NEW_DSD	Age/sex: <1 Female	136		Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	178		Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	117		Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	121		Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	234		Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	972		Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	4,634		Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	650		Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	11,875		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	950		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	6,998		Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	908		Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	10,670		Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	19,526		Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	19,526		Redacted



TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	76,429		Redacted
TX_CURR_DSD	Age/Sex: <1 Male	709		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	1,022		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	1,300		Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	25,583		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	882		Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	1,153		Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	1,545		Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	44,235		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	6,611		Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	709		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	882		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	3,031		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	25,583		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	3,580		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	44,235		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	6,611		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	69,818		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	76,429		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	1,591		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	7,693		Redacted
TX_CURR_TA	Age/Sex: <1 Male	150		Redacted



TX_CURR_TA	Age/Sex: 1-4 Male	89		Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	113		Redacted
TX_CURR_TA	Age/Sex: 15+ Male	2,593		Redacted
TX_CURR_TA	Age/Sex: <1 Female	272		Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	126		Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	168		Redacted
TX_CURR_TA	Age/Sex: 15+ Female	4,182		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	918		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	150		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	272		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	352		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	2,593		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	566		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	4,182		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	918		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	6,775		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	7,693		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	422		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	12,401		Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	126		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	181		Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	130		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	100		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	43		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	212		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	3,517		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	698		Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	171		Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	224		Redacted

TX_NEW_DSD	By Age/Sex: 5-9 Female	148		Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	152		Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	242		Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	1,003		Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	4,784		Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	670		Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	12,401		Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	109		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	537		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	4,470		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	139		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	695		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,699		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	12,401		Redacted
TX_NEW_DSD	Pregnancy status	1,169		Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	9,348		Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	10,507		Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	528		Redacted

TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	400		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	8,420		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	595		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	449		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,463		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	739		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12	8,609		Redacted

	months after initiating ART)			
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	832		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	9,675		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	743		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	990		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	104		Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	112	2	Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service	50		Redacted

	delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services			
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	54		Redacted
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	104		Redacted
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	50		Redacted
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	62		Redacted
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	112		Redacted
FPINT_SITE_DSD	Service delivery type: Community	0		Redacted
FPINT_SITE_DSD	Service delivery type: Clinical	112		Redacted
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	112		Redacted
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	112		Redacted
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	104		Redacted
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	112		Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility	75,945		Redacted

	during the reporting period			
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	84,377		Redacted
TB_SCREEN_DSD	Age: <1	1,487		Redacted
TB_SCREEN_DSD	Age: 1-4	2,029		Redacted
TB_SCREEN_DSD	Age: 5-9	1,393		Redacted
TB_SCREEN_DSD	Age: 10-14	1,263		Redacted
TB_SCREEN_DSD	Age: 15-19	1,813		Redacted
TB_SCREEN_DSD	Age: 20-24	7,720		Redacted
TB_SCREEN_DSD	Age: 25-49	51,764		Redacted
TB_SCREEN_DSD	Age: 50+	8,476		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	7,985		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	6,171		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	69,774		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	75,945		Redacted
TB_SCREEN_DSD	Sex: Male	28,455		Redacted
TB_SCREEN_DSD	Sex: Female	47,490		Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	75,945		Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	10,228		Redacted

Implementing Mechanism Details

Mechanism ID: 10703	Mechanism Name: MSH-SIAPS (Systems for Improved Access to Pharmaceuticals and Services Program)
Funding Agency: USAID	Procurement Type: Cooperative Agreement



Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 958,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	958,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	350,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	10703		
Mechanism Name:	MSH-SIAPS (Systems for Improved Access to Pharmaceuticals and Services Program)		
Prime Partner Name:	Management Sciences for Health		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HVTB	89,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	197,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	402,750	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	268,500	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8	
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	8	
LAB_ACC_DSD	Sum of Support Type disaggregates	8	
LAB_ACC_TA	Sum of Support Type disaggregates	8	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	150	
LAB_CAP_DSD	By clinical laboratories	14	



LAB_CAP_DSD	By Point-of-care testing sites	116	
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	0	
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	150	
LAB_CAP_DSD	Sum of Site Support Type disaggregates	150	
LAB_CAP_TA	Sum of Site Support Type disaggregates	150	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	22	44
HRH_PRE	By Graduates: Other	22	44
HRH_PRE	Sum of Graduates disaggreagtes	22	44

Implementing Mechanism Details

Mechanism ID: 11673	Mechanism Name: DoD/USDF Umbutfo Swaziland Defence Force
Funding Agency: DOD	Procurement Type: USG Core
Prime Partner Name: U.S. Department of Defense (Defense)	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 534,912	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	534,912

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Gender: GBV	20,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Human Resources for Health	85,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	11673		
Mechanism Name:	DoD/USDF Umbutfo Swaziland Defence Force		
Prime Partner Name:	U.S. Department of Defense (Defense)		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	50,878	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	119,962	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	85,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	156,168	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVCT	27,440	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	22,852	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	72,612	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_DSD	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	22	22
PMTCT_ARV_DSD	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	22	22
PMTCT_ARV_DSD	Life-long ART (including Option B+)	22	
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	7	22
PMTCT_ARV_DSD	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	15	0
PMTCT_ARV_DSD	Sum of Regimen Type disaggregates	22	0
PMTCT_ARV_DSD	Sum of New and Current disaggregates	22	22
PMTCT_STAT_DSD	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	22	22
PMTCT_STAT_DSD	Number of new ANC and L&D clients	22	22
PMTCT_STAT_DSD	By: Known positives at entry	18	18
PMTCT_STAT_DSD	By: Number of new positives identified	4	4

PMTCT_STAT_DSD	Sum of Positives Status disaggregates	22	22
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	300	800
VMMC_CIRC_DSD	By Age: 15-19	120	350
VMMC_CIRC_DSD	By Age: 20-24	90	250
VMMC_CIRC_DSD	By Age: 25-49	90	
VMMC_CIRC_DSD	Sum of age disaggregates	300	600
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	93	248
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	201	552
VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	6	
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	60	80
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	240	720
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	300	80
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	0	0
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	8,500	1,650
PP_PREV_DSD	Total number of people in the target population	32,000	5,000
PP_PREV_DSD	Age/sex: 10-14 Male	940	0

PP_PREV_DSD	Age/sex: 15-19 Male	1,225	27
PP_PREV_DSD	Age/sex: 20-24 Male	795	93
PP_PREV_DSD	Age/sex: 25-49 Male	563	1,267
PP_PREV_DSD	Age/sex: 50+ Male	216	98
PP_PREV_DSD	Age/sex: 10-14 Female	1,141	0
PP_PREV_DSD	Age/sex: 15-19 Female	1,392	3
PP_PREV_DSD	Age/sex: 20-24 Female	870	10
PP_PREV_DSD	Age/sex: 25-49 Female	975	141
PP_PREV_DSD	Age/sex: 50+ Female	383	11
PP_PREV_DSD	Sum of Age/Sex disaggregates	8,500	1,650
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	2,000	6,372
HTC_TST_DSD	By Test Result: Negative	1,400	4,985
HTC_TST_DSD	By Test Result: Positive	600	1,387
HTC_TST_DSD	Sum of Test Result disaggregates	2,000	6,372
HTC_TST_DSD	Age/sex: <1 Male	26	
HTC_TST_DSD	Age/sex: 1-4 Male	81	
HTC_TST_DSD	Age/sex: 5-9 Male	29	
HTC_TST_DSD	Age/sex: 10-14 Male	16	
HTC_TST_DSD	Age/sex: 15-19 Male	39	
HTC_TST_DSD	Age/sex: 20-24 Male	107	
HTC_TST_DSD	Age/sex: 25-49 Male	319	
HTC_TST_DSD	Age/sex: 50+ Male	100	
HTC_TST_DSD	Age/sex: <1 Female	20	
HTC_TST_DSD	Age/sex: 1-4 Female	63	
HTC_TST_DSD	Age/sex: 5-9 Female	22	
HTC_TST_DSD	Age/sex: 10-14 Female	16	
HTC_TST_DSD	Age/sex: 15-19 Female	170	
HTC_TST_DSD	Age/sex: 20-24 Female	330	
HTC_TST_DSD	Age/sex: 25-49 Female	531	
HTC_TST_DSD	Age/sex: 50+ Female	130	

HTC_TST_DSD	Sum of Age/Sex disaggregates	1,999	
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	152	76
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	565	3,287
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	121	80
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,162	2,929
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	273	156
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	1,727	6,216
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	2,000	6,372
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	3,000	
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	210	
GEND_NORM_DSD	By Age: 15-19	766	
GEND_NORM_DSD	By Age: 20-24	510	
GEND_NORM_DSD	By Age: 25+	1,514	
GEND_NORM_DSD	Sum of Age disaggregates	3,000	
GEND_NORM_DSD	By Sex: Male	1,200	
GEND_NORM_DSD	By Sex: Female	1,800	
GEND_NORM_DSD	Sum of Sex disaggregates	3,000	
GEND_NORM_DSD	By type of activity: Individual	0	
GEND_NORM_DSD	By type of activity: Small Group	2,000	
GEND_NORM_DSD	By type of activity: Community-level	1,000	
GEND_NORM_TA	Sum of Sex disaggregates	3,000	
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,800	3,208

CARE_CURR_DSD	Age/sex: <1 Male	16	4
CARE_CURR_DSD	Age/sex: 1-4 Male	23	16
CARE_CURR_DSD	Age/sex: 5-9 Male	16	8
CARE_CURR_DSD	Age/sex: 10-14 Male	13	10
CARE_CURR_DSD	Age/sex: 15-19 Male	6	20
CARE_CURR_DSD	Age/sex: 20-24 Male	29	827
CARE_CURR_DSD	Age/sex: 25-49 Male	478	660
CARE_CURR_DSD	Age/sex: 50+ Male	95	148
CARE_CURR_DSD	Age/sex: <1 Female	19	2
CARE_CURR_DSD	Age/sex: 1-4 Female	25	10
CARE_CURR_DSD	Age/sex: 5-9 Female	17	16
CARE_CURR_DSD	Age/sex: 10-14 Female	17	12
CARE_CURR_DSD	Age/sex: 15-19 Female	38	16
CARE_CURR_DSD	Age/sex: 20-24 Female	157	212
CARE_CURR_DSD	Age/sex: 25-49 Female	747	1,115
CARE_CURR_DSD	Age/sex: 50+ Female	104	132
CARE_CURR_DSD	Sun of Age/Sex disaggregates	1,800	3,208
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	67	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	607	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	79	
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,047	
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,800	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	600	1,387
CARE_NEW_DSD	Age/sex: <1 Male	6	1

CARE_NEW_DSD	Age/sex: 1-4 Male	10	7
CARE_NEW_DSD	Age/sex: 5-9 Male	7	3
CARE_NEW_DSD	Age/sex: 10-14 Male	6	4
CARE_NEW_DSD	Age/sex: 15-19 Male	3	9
CARE_NEW_DSD	Age/sex: 20-24 Male	11	357
CARE_NEW_DSD	Age/sex: 25-49 Male	177	286
CARE_NEW_DSD	Age/sex: 50+ Male	35	64
CARE_NEW_DSD	Age/sex: <1 Female	6	1
CARE_NEW_DSD	Age/sex: 1-4 Female	10	4
CARE_NEW_DSD	Age/sex: 5-9 Female	6	7
CARE_NEW_DSD	Age/sex: 10-14 Female	6	5
CARE_NEW_DSD	Age/sex: 15-19 Female	12	7
CARE_NEW_DSD	Age/sex: 20-24 Female	47	92
CARE_NEW_DSD	Age/sex: 25-49 Female	225	483
CARE_NEW_DSD	Age/sex: 50+ Female	33	57
CARE_NEW_DSD	Sum of Age/sex disaggregates	600	1,387
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	10	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	81	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	9	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	500	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	600	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	600	
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	54	435
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	54	435
FN_THER_DSD	Age: 5-14	27	12
FN_THER_DSD	Age: 15-17	27	22
FN_THER_DSD	Sum of Age disaggregates	54	435
TB_ART_DSD	The number of registered new and relapse TB	280	187

	cases with documented HIV-positive status who are on ART during TB treatment during the reporting period		
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period	280	257
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	1,380	2,792
TX_CURR_DSD	Age/Sex: <1 Male	13	3
TX_CURR_DSD	Age/Sex: 1-4 Male	19	14
TX_CURR_DSD	Age/Sex: 5-14 Male	24	16
TX_CURR_DSD	Age/Sex: 15+ Male	459	
TX_CURR_DSD	Age/Sex: <1 Female	16	2
TX_CURR_DSD	Age/Sex: 1-4 Female	20	9
TX_CURR_DSD	Age/Sex: 5-14 Female	28	24
TX_CURR_DSD	Age/Sex: 15+ Female	801	
TX_CURR_DSD	Sum of age/sex disaggregates	120	2,792
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	9	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	63	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	13	
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	16	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	55	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	459	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	66	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	800	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	121	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	1,259	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	1,380	

TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	29	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	300	895
TX_NEW_DSD	By Age/Sex: <1 Male	3	1
TX_NEW_DSD	By Age/Sex: 1-4 Male	4	4
TX_NEW_DSD	By Age/Sex: 5-9 Male	4	5
TX_NEW_DSD	By Age/Sex: 10-14 Male	3	3
TX_NEW_DSD	By Age/Sex: 15-19 Male	1	6
TX_NEW_DSD	By Age/Sex: 20-24 Male	6	230
TX_NEW_DSD	By Age/Sex: 25-49 Male	85	184
TX_NEW_DSD	By Age/Sex: 50+ Male	17	41
TX_NEW_DSD	By Age/Sex: <1 Female	4	1
TX_NEW_DSD	By Age/Sex: 1-4 Female	5	3
TX_NEW_DSD	By Age/Sex: 5-9 Female	4	4
TX_NEW_DSD	By Age/Sex: 10-14 Female	4	3
TX_NEW_DSD	By Age/Sex: 15-19 Female	6	4
TX_NEW_DSD	By Age/Sex: 20-24 Female	24	59
TX_NEW_DSD	By Age/Sex: 25-49 Female	114	310
TX_NEW_DSD	By Age/Sex: 50+ Female	16	37
TX_NEW_DSD	Sum of Age/Sex disaggregates	300	895
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	0	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	29	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	130	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	1	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	14	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	126	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	299	
TX_NEW_DSD	Pregnancy status	52	
TX_NEW_DSD	Breastfeeding status	0	

TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	11,325	255
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	1,380	300
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	75	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	57	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,193	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	78	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	59	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,234	

TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	293	
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	1,032	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	298	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	1,082	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	107	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	143	
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	6	1
LAB_CAP_DSD	By clinical laboratories	1	1
LAB_CAP_DSD	By Point-of-care testing sites	5	
LAB_CAP_DSD	By site support type: Direct Service Delivery	6	

	(DSD)		
LAB_CAP_DSD	Sum of Site Support Type disaggregates	6	
LAB_CAP_TA	Sum of Site Support Type disaggregates	6	
HRH_PRE	Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre	3	4
HRH_PRE	By Graduates: Doctors	1	
HRH_PRE	By Graduates: Other	2	2
HRH_PRE	Sum of Graduates disaggreagtes	3	4
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	5	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	9	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	5	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	5	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	9	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	9	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	9	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	5	



TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	1,800	3,208
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	1,800	3,208
TB_SCREEN_DSD	Age: <1	35	6
TB_SCREEN_DSD	Age: 1-4	48	26
TB_SCREEN_DSD	Age: 5-9	33	24
TB_SCREEN_DSD	Age: 10-14	30	22
TB_SCREEN_DSD	Age: 15-19	43	36
TB_SCREEN_DSD	Age: 20-24	183	
TB_SCREEN_DSD	Age: 25-49	1,227	
TB_SCREEN_DSD	Age: 50+	201	
TB_SCREEN_DSD	Sum of Age disaggregates	189	3,208
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	146	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	1,654	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	1,800	
TB_SCREEN_DSD	Sex: Male	674	1,693
TB_SCREEN_DSD	Sex: Female	1,126	1,515
TB_SCREEN_DSD	Sum of Sex disaggregates	1,800	3,208

Implementing Mechanism Details

Mechanism ID: 13144	Mechanism Name: URC-Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13144			
Mechanism Name: URC-Lab			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	49		Redacted
LAB_CAP_DSD	By clinical laboratories	29		Redacted
LAB_CAP_DSD	By Point-of-care testing sites	17		Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	29		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	20		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	49		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	49		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	100		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that perform this testing	150		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	130		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	130		Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	36		Redacted
LAB_PT_DSD	CD4: Number of laboratories that	25		Redacted

	participate in this PT program			
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1		Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1		Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	20		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	20		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	18		Redacted

Implementing Mechanism Details

Mechanism ID: 13630	Mechanism Name: PSI-CPP (Combination
----------------------------	---



	Prevention Program)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	13630		
Mechanism Name:	PSI-CPP (Combination Prevention Program)		
Prime Partner Name:	Population Services International		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 13645	Mechanism Name: EGPAF-EPAS (Eliminating Pediatric AIDS in Swaziland)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13645			
Mechanism Name: EGPAF-EPAS (Eliminating Pediatric AIDS in Swaziland)			
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
------------------	-------	------	------

PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	9,451	
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	10,496	
PMTCT_ARV_TA	Life-long ART (including Option B+)	6,776	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	4,101	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	2,675	
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	6,776	
PMTCT_ARV_TA	Sum of New and Current disaggregates	6,776	
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	27,860	
PMTCT_STAT_TA	Number of new ANC and L&D clients	28,313	
PMTCT_STAT_TA	By: Known positives at entry	5,573	
PMTCT_STAT_TA	By: Number of new positives identified	4,923	
PMTCT_STAT_TA	Sum of Positives Status disaggregates	10,496	
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	9,656	

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	81	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	606	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	82	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	8,887	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	9,656	
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	6,981	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	81	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	606	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	82	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	6,212	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,981	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,981	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	12,754	
TX_CURR_TA	Age/Sex: <1 Male	212	
TX_CURR_TA	Age/Sex: 1-4 Male	94	
TX_CURR_TA	Age/Sex: 5-14 Male	23	
TX_CURR_TA	Age/Sex: 15+ Male	1,054	
TX_CURR_TA	Age/Sex: <1 Female	218	
TX_CURR_TA	Age/Sex: 1-4 Female	97	
TX_CURR_TA	Age/Sex: 5-14 Female	30	
TX_CURR_TA	Age/Sex: 15+ Female	11,026	
TX_CURR_TA	Sum of Age/Sex disaggregations	674	
TX_CURR_TA	Aggregated Age/Sex: <1 Male	212	

TX_CURR_TA	Aggregated Age/Sex: <1 Female	218	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	117	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,054	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	127	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	11,026	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	244	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	12,080	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	12,324	
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	430	
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	7,385	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	80	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	1	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	606	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	80	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	6,776	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	7,385	
TX_NEW_DSD	Pregnancy status	6,776	
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	2,052	
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,359	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	144	

FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	144	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	144	
FPINT_SITE_DSD	Sum of Numerator Site Support Type disaggregates	144	
FPINT_SITE_DSD	By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points	0	
FPINT_SITE_DSD	By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points	144	
FPINT_SITE_DSD	Sum of Denominator Site Support Type disaggregates	144	
FPINT_SITE_DSD	Service delivery type: Community	0	
FPINT_SITE_DSD	Service delivery type: Clinical	144	
FPINT_SITE_DSD	Sum of Service Delivery Type disaggregates	144	
FPINT_SITE_TA	Sum of Denominator Site Support Type disaggregates	144	
FPINT_SITE_TA	Sum of Numerator Site Support Type disaggregates	144	
FPINT_SITE_TA	Sum of Service Delivery Type disaggregates	144	
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical	9,656	



	assessment (WHO staging) OR CD4 count OR viral load		
--	--	--	--

Implementing Mechanism Details

Mechanism ID: 13738	Mechanism Name: EGPAF-PIHTC (Provider-initiated HIV Testing & Counseling)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Elizabeth Glaser Pediatric AIDS Foundation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13738



Mechanism Name:	EGPAF-PIHTC (Provider-initiated HIV Testing & Counseling)		
Prime Partner Name:	Elizabeth Glaser Pediatric AIDS Foundation		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
HTC_TST_DSD	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	80,197		Redacted
HTC_TST_DSD	By Test Result: Negative	66,893		Redacted
HTC_TST_DSD	By Test Result: Positive	13,304		Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	80,197		Redacted
HTC_TST_DSD	Age/sex: <1 Male	1,036		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	3,253		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	1,176		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	641		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	1,553		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	4,302		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	12,781		Redacted

HTC_TST_DSD	Age/sex: 50+ Male	4,006		Redacted
HTC_TST_DSD	Age/sex: <1 Female	798		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	2,515		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	892		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	654		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	6,818		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	13,254		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	21,304		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	5,214		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	80,197		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	6,106		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	22,643		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	4,859		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	46,589		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	10,965		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	69,232		Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	80,197		Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	111,556		Redacted
HTC_TST_TA	By Test Result: Negative	91,601		Redacted
HTC_TST_TA	By Test Result: Positive	19,955		Redacted
HTC_TST_TA	Sum of Test Result disaggregates	111,556		Redacted
HTC_TST_TA	Age/sex: <1 Male	995		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	3,125		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	1,130		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	615		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	1,492		Redacted

HTC_TST_TA	Age/sex: 20-24 Male	4,133		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	12,277		Redacted
HTC_TST_TA	Age/sex: 50+ Male	3,849		Redacted
HTC_TST_TA	Age/sex: <1 Female	1,303		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	4,102		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	1,456		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	1,067		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	11,124		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	21,623		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	34,759		Redacted
HTC_TST_TA	Age/sex: 50+ Female	8,506		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	111,556		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	5,865		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	21,751		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,929		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	76,011		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	13,794		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	97,762		Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	111,556		Redacted

Implementing Mechanism Details

Mechanism ID: 13742	Mechanism Name: C-BLD (Capacity Building and Livelihoods Development)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: FHI 360	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	



G2G: No	Managing Agency:
---------	------------------

Total All Funding Sources: 513,737	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	19,907
GHP-USAID	493,830

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	200,000
Gender: Gender Equality	50,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Food and Nutrition: Commodities	5,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 13742			
Mechanism Name: C-BLD (Capacity Building and Livelihoods Development)			
Prime Partner Name: FHI 360			
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Care	HKID	474,222	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	39,515	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	3,717	
PP_PREV_DSD	Total number of people in the target population	24,567	
PP_PREV_DSD	Age/sex: 10-14 Male	837	
PP_PREV_DSD	Age/sex: 15-19 Male	474	
PP_PREV_DSD	Age/sex: 20-24 Male	424	
PP_PREV_DSD	Age/sex: 25-49 Male	20	
PP_PREV_DSD	Age/sex: 10-14 Female	1,038	
PP_PREV_DSD	Age/sex: 15-19 Female	456	
PP_PREV_DSD	Age/sex: 20-24 Female	448	
PP_PREV_DSD	Age/sex: 25-49 Female	20	
PP_PREV_DSD	Sum of Age/Sex disaggregates	3,717	
GEND_NORM_DSD	Number of people completing an intervention pertaining to gender norms, that meets minimum criteria	0	300
GEND_NORM_DSD	By Age: 0-9	0	
GEND_NORM_DSD	By Age: 10-14	1,500	
GEND_NORM_DSD	By Age: 15-19	1,650	
GEND_NORM_DSD	By Age: 20-24	1,450	
GEND_NORM_DSD	By Age: 25+	1,800	



GEND_NORM_DSD	Sum of Age disaggregates	6,400	
GEND_NORM_DSD	By Sex: Male	2,500	
GEND_NORM_DSD	By Sex: Female	3,900	
GEND_NORM_DSD	Sum of Sex disaggregates	6,400	
GEND_NORM_DSD	By type of activity: Individual	350	
GEND_NORM_DSD	By type of activity: Small Group	2,500	
GEND_NORM_DSD	By type of activity: Community-level	3,550	
GEND_NORM_TA	Sum of Sex disaggregates	6,400	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	11,070	7,000
OVC_SERV_DSD	Sex: Male	4,539	
OVC_SERV_DSD	Sex: Female	6,531	
OVC_SERV_DSD	Sum of Sex disaggregates	11,070	
OVC_SERV_DSD	Age: <1	1,440	
OVC_SERV_DSD	Age: 1-4	1,455	
OVC_SERV_DSD	Age: 5-9	1,845	
OVC_SERV_DSD	Age: 10-14	1,980	
OVC_SERV_DSD	Age: 15-17	2,505	
OVC_SERV_DSD	Age: 18+	1,845	
OVC_SERV_DSD	Sum of Age disaggregates	11,070	

Implementing Mechanism Details

Mechanism ID: 13791	Mechanism Name: PSI-CIHTC (Client-initiated HIV Testing & Counseling)
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,028,842	
---	--



Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,028,842

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	125,000
Gender: Gender Equality	100,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Food and Nutrition: Policy, Tools, and Service Delivery	100,000
Gender: GBV	50,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID: 13791			
Mechanism Name: PSI-CIHTC (Client-initiated HIV Testing & Counseling)			
Prime Partner Name: Population Services International			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	102,884	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	61,730	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	102,884	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	607,017	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	102,885	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	51,442	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the	12,100		Redacted

	reporting period.			
PP_PREV_DSD	Total number of people in the target population	324,484		Redacted
PP_PREV_DSD	Age/sex: 10-14 Male	1,661		Redacted
PP_PREV_DSD	Age/sex: 15-19 Male	2,998		Redacted
PP_PREV_DSD	Age/sex: 20-24 Male	1,331		Redacted
PP_PREV_DSD	Age/sex: 25-49 Male	665		Redacted
PP_PREV_DSD	Age/sex: 50+ Male	0		Redacted
PP_PREV_DSD	Age/sex: 15-19 Female	1,364		Redacted
PP_PREV_DSD	Age/sex: 20-24 Female	2,453		Redacted
PP_PREV_DSD	Age/sex: 25-49 Female	1,089		Redacted
PP_PREV_DSD	Age/sex: 50+ Female	539		Redacted
PP_PREV_DSD	Sum of Age/Sex disaggregates	12,100		Redacted
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	400		Redacted
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	250		Redacted
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	150		Redacted
HTC_TST_DSD	Number of individuals who received	83,600	97,382	Redacted

	T&C services for HIV and received their test results during the past 12 months			
HTC_TST_DSD	By Test Result: Negative	75,240	87,598	Redacted
HTC_TST_DSD	By Test Result: Positive	8,360	9,784	Redacted
HTC_TST_DSD	Sum of Test Result disaggregates	83,600	97,382	Redacted
HTC_TST_DSD	Age/sex: <1 Male	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Male	2,508		Redacted
HTC_TST_DSD	Age/sex: 5-9 Male	2,508		Redacted
HTC_TST_DSD	Age/sex: 10-14 Male	16,720		Redacted
HTC_TST_DSD	Age/sex: 15-19 Male	836		Redacted
HTC_TST_DSD	Age/sex: 20-24 Male	6,688		Redacted
HTC_TST_DSD	Age/sex: 25-49 Male	20,064		Redacted
HTC_TST_DSD	Age/sex: 50+ Male	836		Redacted
HTC_TST_DSD	Age/sex: <1 Female	0		Redacted
HTC_TST_DSD	Age/sex: 1-4 Female	836		Redacted
HTC_TST_DSD	Age/sex: 5-9 Female	2,508		Redacted
HTC_TST_DSD	Age/sex: 10-14 Female	4,180		Redacted
HTC_TST_DSD	Age/sex: 15-19 Female	5,016		Redacted
HTC_TST_DSD	Age/sex: 20-24 Female	4,180		Redacted
HTC_TST_DSD	Age/sex: 25-49 Female	15,884		Redacted
HTC_TST_DSD	Age/sex: 50+ Female	836		Redacted
HTC_TST_DSD	Sum of Age/Sex disaggregates	83,600		Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	21,736	6,075	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	28,424	63,320	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	7,524	2,617	Redacted
HTC_TST_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,916	25,370	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex <15	29,260	8,692	Redacted
HTC_TST_DSD	Sum of Aggregated Age/Sex 15+	54,340	88,690	Redacted



HTC_TST_DSD	Sum of Aggregated Age/Sex disaggregates	83,600	97,382	Redacted
-------------	--	--------	--------	----------

Implementing Mechanism Details

Mechanism ID: 14201	Mechanism Name: M2M (Mothers 2 Mothers)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Mothers 2 Mothers	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,299,621	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,299,621

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	20
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Food and Nutrition: Policy, Tools, and Service Delivery	20
Water	20



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14201			
Mechanism Name: M2M (Mothers 2 Mothers)			
Prime Partner Name: Mothers 2 Mothers			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	43,177	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	205,121	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	1,051,323	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	13,611	
PP_PREV_DSD	Total number of people in the target population	14,000	
PP_PREV_DSD	Age/sex: 25-49 Female	13,611	
PP_PREV_DSD	Sum of Age/Sex disaggregates	13,611	

Implementing Mechanism Details

Mechanism ID: 14374	Mechanism Name: APHL
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Association of Public Health Laboratories	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 14374			
Mechanism Name: APHL			
Prime Partner Name: Association of Public Health Laboratories			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 14842	Mechanism Name: Public Diplomacy
Funding Agency: State/AF	Procurement Type: USG Core
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 51,570	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	51,570

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	15,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 14842			
Mechanism Name: Public Diplomacy			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	51,570	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16760	Mechanism Name: URC-ASSIST
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-USAID	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16760			
Mechanism Name: URC-ASSIST			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,405	
CARE_CURR_TA	Age/sex: <1 Male	10	
CARE_CURR_TA	Age/sex: 1-4 Male	10	
CARE_CURR_TA	Age/sex: 5-9 Male	20	
CARE_CURR_TA	Age/sex: 10-14 Male	30	
CARE_CURR_TA	Age/sex: 15-19 Male	155	
CARE_CURR_TA	Age/sex: 20-24 Male	467	
CARE_CURR_TA	Age/sex: 25-49 Male	411	
CARE_CURR_TA	Age/sex: 50+ Male	100	
CARE_CURR_TA	Age/sex: <1 Female	5	
CARE_CURR_TA	Age/sex: 1-4 Female	10	
CARE_CURR_TA	Age/sex: 5-9 Female	42	
CARE_CURR_TA	Age/sex: 10-14 Female	30	
CARE_CURR_TA	Age/sex: 15-19 Female	171	
CARE_CURR_TA	Age/sex: 20-24 Female	431	
CARE_CURR_TA	Age/sex: 25-49 Female	421	
CARE_CURR_TA	Age/sex: 50+ Female	92	
CARE_CURR_TA	Sum of Age/Sex disaggregates	2,405	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	70	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,133	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	87	
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,115	
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,405	
CARE_NEW_DSD	Number of HIV-infected adults and children	6,050	

	newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load		
CARE_NEW_DSD	Age/sex: <1 Male	20	
CARE_NEW_DSD	Age/sex: 1-4 Male	101	
CARE_NEW_DSD	Age/sex: 5-9 Male	61	
CARE_NEW_DSD	Age/sex: 10-14 Male	60	
CARE_NEW_DSD	Age/sex: 15-19 Male	121	
CARE_NEW_DSD	Age/sex: 20-24 Male	171	
CARE_NEW_DSD	Age/sex: 25-49 Male	2,128	
CARE_NEW_DSD	Age/sex: 50+ Male	539	
CARE_NEW_DSD	Age/sex: <1 Female	20	
CARE_NEW_DSD	Age/sex: 1-4 Female	137	
CARE_NEW_DSD	Age/sex: 5-9 Female	61	
CARE_NEW_DSD	Age/sex: 10-14 Female	61	
CARE_NEW_DSD	Age/sex: 15-19 Female	141	
CARE_NEW_DSD	Age/sex: 20-24 Female	282	
CARE_NEW_DSD	Age/sex: 25-49 Female	1,815	
CARE_NEW_DSD	Age/sex: 50+ Female	333	
CARE_NEW_DSD	Sum of Age/sex disaggregates	6,051	
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	242	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	2,959	
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	278	
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	2,571	
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	6,050	
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	6,050	
TB_ART_DSD	The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period	2,700	
TB_ART_DSD	The number of registered new and relapse TB	3,000	

	cases with documented HIV-positive status during TB treatment during the reporting period		
TB_ART_DSD	Age: 0-4	135	
TB_ART_DSD	Age: 5-14	108	
TB_ART_DSD	Age: 15+	2,457	
TB_ART_DSD	Male	1,431	
TB_ART_DSD	Female	1,269	
TB_ART_DSD	Sum of Sex disaggregates	2,700	
TB_ART_DSD	Newly tested	900	
TB_ART_DSD	Known HIV-positive	2,100	
TB_ART_DSD	Sum of Test Status disaggregates	3,000	
TB_ART_DSD	Aggregated Age: <15	243	
TB_ART_DSD	Aggregated Age: 15+	2,457	
TB_ART_DSD	Sum of Aggregated Age disaggregates	2,700	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	600	
TX_CURR_DSD	Age/Sex: <1 Male	3	
TX_CURR_DSD	Age/Sex: 1-4 Male	11	
TX_CURR_DSD	Age/Sex: 5-14 Male	12	
TX_CURR_DSD	Age/Sex: 15+ Male	278	
TX_CURR_DSD	Age/Sex: <1 Female	3	
TX_CURR_DSD	Age/Sex: 1-4 Female	13	
TX_CURR_DSD	Age/Sex: 5-14 Female	12	
TX_CURR_DSD	Age/Sex: 15+ Female	268	
TX_CURR_DSD	Sum of age/sex disaggregates	54	
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	5	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	49	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	3	

TX_CURR_DSD	Aggregated Age/Sex: <1 Female	3	
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	26	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	278	
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	28	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	268	
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	54	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	546	
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	600	
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	6	
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,125	
TX_CURR_TA	Age/Sex: <1 Male	3	
TX_CURR_TA	Age/Sex: 1-4 Male	21	
TX_CURR_TA	Age/Sex: 5-14 Male	37	
TX_CURR_TA	Age/Sex: 15+ Male	991	
TX_CURR_TA	Age/Sex: <1 Female	3	
TX_CURR_TA	Age/Sex: 1-4 Female	29	
TX_CURR_TA	Age/Sex: 5-14 Female	44	
TX_CURR_TA	Age/Sex: 15+ Female	997	
TX_CURR_TA	Sum of Age/Sex disaggregations	137	
TX_CURR_TA	Aggregated Age/Sex: <1 Male	3	
TX_CURR_TA	Aggregated Age/Sex: <1 Female	3	
TX_CURR_TA	Aggregated Age/Sex: <15 Male	61	
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	991	
TX_CURR_TA	Aggregated Age/Sex: <15 Female	76	
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	997	
TX_CURR_TA	Sum of Aggregated Age/Sex <15	137	
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	1,988	
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,125	
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	6	

TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	939	
TX_NEW_DSD	By Age/Sex: <1 Male	2	
TX_NEW_DSD	By Age/Sex: 1-4 Male	20	
TX_NEW_DSD	By Age/Sex: 5-9 Male	10	
TX_NEW_DSD	By Age/Sex: 10-14 Male	9	
TX_NEW_DSD	By Age/Sex: 15-19 Male	17	
TX_NEW_DSD	By Age/Sex: 20-24 Male	30	
TX_NEW_DSD	By Age/Sex: 25-49 Male	272	
TX_NEW_DSD	By Age/Sex: 50+ Male	83	
TX_NEW_DSD	By Age/Sex: <1 Female	3	
TX_NEW_DSD	By Age/Sex: 1-4 Female	22	
TX_NEW_DSD	By Age/Sex: 5-9 Female	10	
TX_NEW_DSD	By Age/Sex: 10-14 Female	9	
TX_NEW_DSD	By Age/Sex: 15-19 Female	26	
TX_NEW_DSD	By Age/Sex: 20-24 Female	40	
TX_NEW_DSD	By Age/Sex: 25-49 Female	337	
TX_NEW_DSD	By Age/Sex: 50+ Female	49	
TX_NEW_DSD	Sum of Age/Sex disaggregates	939	
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	2	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	43	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	450	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	3	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	46	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	400	
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	939	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	91,300	
TB_SCREEN_DSD	Age: <1	2	



TB_SCREEN_DSD	Age: 1-4	10	
TB_SCREEN_DSD	Age: 5-9	15	
TB_SCREEN_DSD	Age: 10-14	15	
TB_SCREEN_DSD	Age: 15-19	41	
TB_SCREEN_DSD	Age: 20-24	53	
TB_SCREEN_DSD	Age: 25-49	318	
TB_SCREEN_DSD	Age: 50+	141	
TB_SCREEN_DSD	Sum of Age disaggregates	83	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	42	
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	553	
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	595	
TB_SCREEN_DSD	Sex: Male	276	
TB_SCREEN_DSD	Sex: Female	319	
TB_SCREEN_DSD	Sum of Sex disaggregates	595	
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	2,405	

Implementing Mechanism Details

Mechanism ID: 16812	Mechanism Name: ASLM
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: African Society for Laboratory Medicine	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GAP	0
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16812 Mechanism Name: ASLM Prime Partner Name: African Society for Laboratory Medicine			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16815	Mechanism Name: Health Finance & Governance Project (HFG)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Abt Associates	



Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 600,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	600,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	440,000
----------------------------	---------

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16815			
Mechanism Name: Health Finance & Governance Project (HFG)			
Prime Partner Name: Abt Associates			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	600,000	0

Implementing Mechanism Indicator Information



(No data provided.)

Implementing Mechanism Details

Mechanism ID: 16821	Mechanism Name: Health Communication Capacity Collaborative (HC3)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 1,260,307	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,260,307

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Sub Area:	Monitoring and Evaluation
Gender: Gender Equality	50,000
Focus Area:	Promoting gender-related policies and laws that increase legal protection
Sub Area:	Collection and Use of Gender-related Strategic



	Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Implementation
Sub Area:	Capacity building
Condom programming	50,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 16821			
Mechanism Name: Health Communication Capacity Collaborative (HC3)			
Prime Partner Name: Johns Hopkins University Bloomberg School of Public Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	60,195	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	1,235	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	2,058	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	12,144	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Prevention	HVOP	1,181,588	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	2,058	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	1,029	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
KP_PREV_DSD	Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required	300	3,636
KP_PREV_DSD	By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	200	2,600
KP_PREV_DSD	By key population type: Men who have sex with men/Transgender (MSM/TG) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)	100	777
GEND_NORM_DSD	By Age: 15-19	5,580	
GEND_NORM_DSD	By Age: 20-24	5,580	
GEND_NORM_DSD	By Age: 25+	22,320	
GEND_NORM_DSD	Sum of Age disaggregates	33,480	



GEND_NORM_DSD	By Sex: Male	16,740	
GEND_NORM_DSD	By Sex: Female	16,740	
GEND_NORM_DSD	Sum of Sex disaggregates	33,480	
GEND_NORM_DSD	By type of activity: Small Group	33,480	
GEND_NORM_TA	Sum of Sex disaggregates	33,480	

Implementing Mechanism Details

Mechanism ID: 17096	Mechanism Name: Together for Girls (MCH Umbrella Grant)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: United Nations Children's Fund	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	17096		
Mechanism Name:	Together for Girls (MCH Umbrella Grant)		
Prime Partner Name:	United Nations Children's Fund		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17389	Mechanism Name: Vast Grants
Funding Agency: PC	Procurement Type: Grant
Prime Partner Name: U.S. Peace Corps	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 54,603	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	54,603

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Economic Strengthening	5,000
Education	5,000



Gender: Gender Equality	3,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17389		
Mechanism Name:	Vast Grants		
Prime Partner Name:	U.S. Peace Corps		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	54,603	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
OVC_SERV_DSD	Sex: Male	750	
OVC_SERV_DSD	Sex: Female	850	
OVC_SERV_DSD	Sum of Sex disaggregates	1,600	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	0	
OVC_SERV_DSD	Age: 5-9	160	
OVC_SERV_DSD	Age: 10-14	480	
OVC_SERV_DSD	Age: 15-17	480	
OVC_SERV_DSD	Age: 18+	480	
OVC_SERV_DSD	Sum of Age disaggregates	1,600	



Implementing Mechanism Details

Mechanism ID: 17454	Mechanism Name: CHAPS VMMC
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Swaziland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,631,464	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,631,464

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Condom programming	150,000
Gender: Gender Equality	75,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17454			
Mechanism Name: CHAPS VMMC			
Prime Partner Name: Centre for HIV and AIDS Prevention Studies Swaziland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	319,035	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	2,283,949	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	28,480	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
VMMC_CIRC_DSD	Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period	12,000	11,700
VMMC_CIRC_DSD	By Age: <1	2,000	0
VMMC_CIRC_DSD	By Age: 1-9	0	0
VMMC_CIRC_DSD	By Age: 10-14	6,900	3,290
VMMC_CIRC_DSD	By Age: 15-19	1,800	5,223
VMMC_CIRC_DSD	By Age: 20-24	800	1,526
VMMC_CIRC_DSD	By Age: 25-49	500	
VMMC_CIRC_DSD	By Age: 50+	0	0
VMMC_CIRC_DSD	Sum of age disaggregates	12,000	10,039
VMMC_CIRC_DSD	By HIV status: Number of HIV-positive clients (tested HIV positive at VMMC site)	40	312
VMMC_CIRC_DSD	By HIV status: Number of HIV-negative clients (tested HIV negative at VMMC program)	9,000	8,383

VMMC_CIRC_DSD	By HIV status: Number of clients with undocumented/indeterminate HIV status or not tested for HIV at site	960	3,005
VMMC_CIRC_DSD	By circumcision technique: Surgical VMMC	10,000	11,700
VMMC_CIRC_DSD	By circumcision technique: Device-based VMMC	2,000	0
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who returned at least once for follow-up care within 14 days of circumcision surgery	9,800	11,700
VMMC_CIRC_DSD	By follow-up status: Number of surgically circumcised clients who did NOT return for follow-up care within 14 days of circumcision surgery	200	0

Implementing Mechanism Details

Mechanism ID: 17455	Mechanism Name: PEPFAR Small Grants Program
Funding Agency: State/AF	Procurement Type: Grant
Prime Partner Name: U.S. Department of State	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 51,570	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	51,570

Sub Partner Name(s)

(No data provided.)



Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	5,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Economic Strengthening	5,000
Education	5,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17455			
Mechanism Name: PEPFAR Small Grants Program			
Prime Partner Name: U.S. Department of State			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	51,570	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17458	Mechanism Name: ICAP – Epi-Research TA
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 1,200,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	1,200,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Gender: Gender Equality	50,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17458		
Mechanism Name:	ICAP – Epi-Research TA		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and	HVSI	1,000,000	0



Systems			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17460	Mechanism Name: URC - Lubombo
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: University Research Corporation, LLC	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 4,061,946	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	4,061,946

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
Food and Nutrition: Policy, Tools, and Service Delivery	150,000
Gender: GBV	75,000
Focus Area:	Post GBV Care



Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	100,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Capacity building
Motor Vehicles: Purchased	190,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17460			
Mechanism Name: URC - Lubombo			
Prime Partner Name: University Research Corporation, LLC			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	294,322	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	75,882	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	183,773	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	225,919	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount

Prevention	MTCT	59,487	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,014,754	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	207,809	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_DS D	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	0	1,856	Redacted
PMTCT_ARV_DS D	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	0	2,061	Redacted
PMTCT_ARV_DS D	Life-long ART (including Option B+)	0		Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	0	889	Redacted
PMTCT_ARV_DS D	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	0	959	Redacted
PMTCT_ARV_DS D	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_DS D	Maternal AZT (prophylaxis component of WHO Option A during pregnancy)	0		Redacted

	and delivery)			
PMTCT_ARV_DS D	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_DS D	Sum of Regimen Type disaggregates	0		Redacted
PMTCT_ARV_DS D	Sum of New and Current disaggregates	0	1,848	Redacted
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	2,550	75	Redacted
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	2,832	82	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	1,828		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,107	34	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	722	41	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	1,828		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	1,829	75	Redacted
PMTCT_STAT_DS D	Number of pregnant women with known HIV status (includes women who were	0	5,689	Redacted

	tested for HIV and received their results)			
PMTCT_STAT_DS D	Number of new ANC and L&D clients	0	5,990	Redacted
PMTCT_STAT_DS D	By: Known positives at entry	0	573	Redacted
PMTCT_STAT_DS D	By: Number of new positives identified	0	1,585	Redacted
PMTCT_STAT_DS D	Sum of Positives Status disaggregates	0	2,158	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	6,129	57	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	6,229	59	Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,226	30	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,083	7	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	2,309	37	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	24,315	1,930	Redacted
HTC_TST_TA	By Test Result: Negative	19,989	1,111	Redacted
HTC_TST_TA	By Test Result: Positive	4,326	96	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	24,315	1,207	Redacted
HTC_TST_TA	Age/sex: <1 Male	219		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	686		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	247		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	133		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	327		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	898		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	2,619		Redacted
HTC_TST_TA	Age/sex: 50+ Male	829		Redacted
HTC_TST_TA	Age/sex: <1 Female	286		Redacted

HTC_TST_TA	Age/sex: 1-4 Female	901		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	319		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	233		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	2,443		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	4,742		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	7,586		Redacted
HTC_TST_TA	Age/sex: 50+ Female	1,845		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	24,313		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,285	312	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	4,674	582	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,740	543	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	1,667	493	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	3,025	855	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	6,341	1,075	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	9,366	1,930	Redacted
CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	20,250	32,279	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	177	448	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	255	1,316	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	183	1,586	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	141	1,811	Redacted
CARE_CURR_DS	Age/sex: 15-19 Male	66	1,899	Redacted

D				
CARE_CURR_DS D	Age/sex: 20-24 Male	325	3,285	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	5,374	3,943	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,066	1,663	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	219	958	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	286	1,296	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	189	1,571	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	194	1,830	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	425	1,929	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	1,763	3,499	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Female	8,408	3,604	Redacted
CARE_CURR_DS D	Age/sex: 50+ Female	1,178	1,583	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	20,249	32,221	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	757		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	6,831		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	888		Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	11,774		Redacted
CARE_CURR_DS	Sum of Aggregated Age/Sex	20,250		Redacted

D	disaggregates			
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,023	645	Redacted
CARE_CURR_TA	Age/sex: <1 Male	27	9	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	38	35	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	28	38	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	21	37	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	10	35	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	51	42	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	840	106	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	166	35	Redacted
CARE_CURR_TA	Age/sex: <1 Female	44	35	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	58	35	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	38	37	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	39	37	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	60	36	Redacted
CARE_CURR_TA	Age/sex: 20-24 Female	249	32	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,187	64	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	166	32	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	3,022	645	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	3,182	5,722	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	33	99	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	54	218	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	39	294	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	30	320	Redacted

CARE_NEW_DSD	Age/sex: 15-19 Male	18	390	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	58	557	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	940	676	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	186	301	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	34	117	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	51	213	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	32	294	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	31	339	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	64	412	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Female	247	602	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,187	607	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	177	281	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	3,181	5,720	Redacted
FN_THER_DSD	Number of clinically malnourished PLHIV who received therapeutic and/or supplementary food during the reporting period.	47		Redacted
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	47		Redacted
FN_THER_DSD	Age: <1	0		Redacted
FN_THER_DSD	Age: 1-4	1		Redacted
FN_THER_DSD	Age: 5-14	6		Redacted
FN_THER_DSD	Age: 15-17	8		Redacted
FN_THER_DSD	Age: 18+	31		Redacted
FN_THER_DSD	Sum of Age disaggregates	46		Redacted
FN_THER_DSD	Aggregated Age: <18	16		Redacted
FN_THER_DSD	Aggregated Age: 18+	31		Redacted
FN_THER_DSD	Sum of Aggregated Age disaggregates	47		Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	2,749	1,985	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant	2,832		Redacted

	women identified during the reporting period (include known HIV-positive women at entry into PMTCT)			
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	2,474	1,832	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	275	142	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	2,749	1,974	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	110		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	18,343	28,068	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	170	373	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	245	1,375	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	312	2,764	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	6,140		Redacted
TX_CURR_DSD	Age/Sex: <1 Female	212	377	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	277	1,376	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	371	2,756	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	10,616		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	1,587	28,065	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	170		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	212		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	727		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	6,140		Redacted

TX_CURR_DSD	Aggregated Age/Sex: <15 Female	859		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	10,616		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	1,586		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	16,756		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	18,342		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	382		Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	2,880	562	Redacted
TX_CURR_TA	Age/Sex: <1 Male	54	8	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	37	30	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	31	65	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	720		Redacted
TX_CURR_TA	Age/Sex: <1 Female	85	8	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	47	29	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	46	64	Redacted
TX_CURR_TA	Age/Sex: 15+ Female	1,860		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	300	562	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	56		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	102		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	132		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	970	0	Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	212		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	1,566	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	344		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	2,536	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	2,880	0	Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	158	0	Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	2,841	5,704	Redacted

TX_NEW_DSD	By Age/Sex: <1 Male	28	93	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	42	282	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	33	315	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	28	323	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	11	320	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	49	367	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	799	816	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	161	254	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	38	94	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	51	280	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	33	322	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	34	332	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	56	338	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	225	373	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,100	921	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	153	275	Redacted
TX_NEW_DSD	Sum of Age/Sex disaggregates	2,841	5,705	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	7		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	99		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,207		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	12		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	143		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	1,392		Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	2,841		Redacted
TX_NEW_DSD	Pregnancy status	1,864		Redacted
TX_NEW_DSD	Breastfeeding status	0	0	Redacted
TX_RET_DSD	Number of adults and children who are	2,214	2,135	Redacted

	still alive and on treatment at 12 months after initiating ART			
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	2,522	2,513	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	127		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	96		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,120		Redacted
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	143		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	108		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART)	2,271		Redacted

	in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	177		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	2,066		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	200		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	2,322		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	178		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the	238		Redacted

	reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)			
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	27	3	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	27	3	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	6,076	29,051	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	20,250	32,279	Redacted
TB_SCREEN_DSD	Age: <1	119	684	Redacted
TB_SCREEN_DSD	Age: 1-4	162	2,397	Redacted
TB_SCREEN_DSD	Age: 5-9	111	2,699	Redacted
TB_SCREEN_DSD	Age: 10-14	101	2,836	Redacted
TB_SCREEN_DSD	Age: 15-19	145	4,144	Redacted
TB_SCREEN_DSD	Age: 20-24	618		Redacted
TB_SCREEN_DSD	Age: 25-49	4,141		Redacted
TB_SCREEN_DSD	Age: 50+	678		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	638	29,051	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	494		Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	5,582		Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	6,076		Redacted
TB_SCREEN_DSD	Sex: Male	2,276	13,985	Redacted



TB_SCREEN_DSD	Sex: Female	3,799	15,066	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	6,075	29,051	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	3,023	645	Redacted

Implementing Mechanism Details

Mechanism ID: 17461	Mechanism Name: ICAP Lab
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 2,756,640	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	2,756,640

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	100,000
----------------------------	---------

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	17461		
Mechanism Name:	ICAP Lab		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	690,668	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	641,125	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	94,632	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	662,423	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	100,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	473,160	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	94,632	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning
------------------	-------	------	------	----------

				Budget Targets
LAB_ACC_DSD	Number of PEPFAR-supported testing facilities (laboratories) that are recognized by national, regional, or international standards for accreditation or have achieved a minimal acceptable level towards attainment of such accreditation	8	2	Redacted
LAB_ACC_DSD	By site support type: Direct Service Delivery (DSD)	8		Redacted
LAB_ACC_DSD	By site support type: Technical Assistance-only (TA)	0		Redacted
LAB_ACC_DSD	Sum of Support Type disaggregates	8		Redacted
LAB_ACC_TA	Sum of Support Type disaggregates	8		Redacted
LAB_CAP_DSD	Number of PEPFAR-supported testing facilities with capacity to perform clinical laboratory tests	150	98	Redacted
LAB_CAP_DSD	By clinical laboratories	0	58	Redacted
LAB_CAP_DSD	By Point-of-care testing sites	136	40	Redacted
LAB_CAP_DSD	By site support type: Direct Service Delivery (DSD)	29		Redacted
LAB_CAP_DSD	By site support type: Technical Assistance-only (TA)	121		Redacted
LAB_CAP_DSD	Sum of Site Support Type disaggregates	150		Redacted
LAB_CAP_TA	Sum of Site Support Type disaggregates	150		Redacted
LAB_PT_DSD	Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program	100		Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing:	150	482	Redacted

	Number of laboratories that perform this testing			
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program	130	482	Redacted
LAB_PT_DSD	HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program	130	482	Redacted
LAB_PT_DSD	CD4: Number of laboratories that perform this testing	36	90	Redacted
LAB_PT_DSD	CD4: Number of laboratories that participate in this PT program	36	90	Redacted
LAB_PT_DSD	CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program	25	90	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that perform this testing	1	2	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that participate in this PT program	1	2	Redacted
LAB_PT_DSD	Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that perform this testing	1	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that participate in this PT program	1	2	Redacted
LAB_PT_DSD	HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program	1	2	Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that perform this testing	20		Redacted



LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that participate in this PT program	20		Redacted
LAB_PT_DSD	TB diagnostics (AFB microscopy, Xpert MTB/RIF, Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program	18		Redacted

Implementing Mechanism Details

Mechanism ID: 17462	Mechanism Name: Strengthening MOH Leadership, Governance & Quality Management
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: Ministry of Health- Swaziland	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: Yes	Managing Agency: HHS/CDC

Total All Funding Sources: 689,500	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	689,500

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	220,000
----------------------------	---------



Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17462			
Mechanism Name: Strengthening MOH Leadership, Governance & Quality Management			
Prime Partner Name: Ministry of Health- Swaziland			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	89,500	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	197,250	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	402,750	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17463	Mechanism Name: ICAP-Manzini
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: International Center for AIDS Care and Treatment Programs, Columbia University	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,297,575	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	5,297,575

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Gender: GBV	75,000
Focus Area:	GBV Prevention
Sub Area:	Collection and Use of Gender-related Strategic Information
Gender: Gender Equality	100,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Capacity building
Motor Vehicles: Purchased	190,000

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	17463		
Mechanism Name:	ICAP-Manzini		
Prime Partner Name:	International Center for AIDS Care and Treatment Programs, Columbia University		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	422,663	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	175,113	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	256,043	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	257,049	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	98,427	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	3,798,748	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	289,532	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016	Planning Budget Targets
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to	3,450	56	Redacted

	reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery			
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,832	67	Redacted
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,474		Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,497	34	Redacted
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	977	22	Redacted
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0		Redacted
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0		Redacted
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0		Redacted
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	2,474		Redacted
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,474	56	Redacted
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results)	8,058	191	Redacted
PMTCT_STAT_TA	Number of new ANC and L&D clients	8,262	200	Redacted
PMTCT_STAT_TA	By: Known positives at entry	1,601	160	Redacted
PMTCT_STAT_TA	By: Number of new positives identified	1,401	31	Redacted
PMTCT_STAT_TA	Sum of Positives Status disaggregates	3,002	191	Redacted
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	48,631	1,846	Redacted



HTC_TST_TA	By Test Result: Negative	39,979	1,596	Redacted
HTC_TST_TA	By Test Result: Positive	8,652	250	Redacted
HTC_TST_TA	Sum of Test Result disaggregates	48,631	1,846	Redacted
HTC_TST_TA	Age/sex: <1 Male	437		Redacted
HTC_TST_TA	Age/sex: 1-4 Male	1,373		Redacted
HTC_TST_TA	Age/sex: 5-9 Male	494		Redacted
HTC_TST_TA	Age/sex: 10-14 Male	267		Redacted
HTC_TST_TA	Age/sex: 15-19 Male	653		Redacted
HTC_TST_TA	Age/sex: 20-24 Male	1,797		Redacted
HTC_TST_TA	Age/sex: 25-49 Male	5,239		Redacted
HTC_TST_TA	Age/sex: 50+ Male	1,659		Redacted
HTC_TST_TA	Age/sex: <1 Female	572		Redacted
HTC_TST_TA	Age/sex: 1-4 Female	1,802		Redacted
HTC_TST_TA	Age/sex: 5-9 Female	638		Redacted
HTC_TST_TA	Age/sex: 10-14 Female	467		Redacted
HTC_TST_TA	Age/sex: 15-19 Female	4,886		Redacted
HTC_TST_TA	Age/sex: 20-24 Female	9,485		Redacted
HTC_TST_TA	Age/sex: 25-49 Female	15,172		Redacted
HTC_TST_TA	Age/sex: 50+ Female	3,690		Redacted
HTC_TST_TA	Sum of Age/Sex disaggregates	48,631		Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	2,570	69	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	9,347	878	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	3,480	66	Redacted
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	33,234	833	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex <15	6,050	135	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	42,581	1,711	Redacted
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	48,631	1,846	Redacted

CARE_CURR_DS D	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	33,751	44,036	Redacted
CARE_CURR_DS D	Age/sex: <1 Male	295	59	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Male	426	287	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Male	306	345	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Male	236	435	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Male	111	286	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Male	541	479	Redacted
CARE_CURR_DS D	Age/sex: 25-49 Male	8,957	10,423	Redacted
CARE_CURR_DS D	Age/sex: 50+ Male	1,777	2,508	Redacted
CARE_CURR_DS D	Age/sex: <1 Female	364	63	Redacted
CARE_CURR_DS D	Age/sex: 1-4 Female	476	294	Redacted
CARE_CURR_DS D	Age/sex: 5-9 Female	314	413	Redacted
CARE_CURR_DS D	Age/sex: 10-14 Female	324	402	Redacted
CARE_CURR_DS D	Age/sex: 15-19 Female	708	1,008	Redacted
CARE_CURR_DS D	Age/sex: 20-24 Female	2,938	3,682	Redacted
CARE_CURR_DS	Age/sex: 25-49 Female	14,014	19,307	Redacted

D				
CARE_CURR_DS D	Age/sex: 50+ Female	1,964	4,045	Redacted
CARE_CURR_DS D	Sun of Age/Sex disaggregates	33,751	44,036	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,262	42	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	11,385	536	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,480	39	Redacted
CARE_CURR_DS D	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	19,624	1,199	Redacted
CARE_CURR_DS D	Sum of Aggregated Age/Sex disaggregates	33,751	1,816	Redacted
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,038	1,579	Redacted
CARE_CURR_TA	Age/sex: <1 Male	45	0	Redacted
CARE_CURR_TA	Age/sex: 1-4 Male	64	0	Redacted
CARE_CURR_TA	Age/sex: 5-9 Male	46	0	Redacted
CARE_CURR_TA	Age/sex: 10-14 Male	35	0	Redacted
CARE_CURR_TA	Age/sex: 15-19 Male	17	0	Redacted
CARE_CURR_TA	Age/sex: 20-24 Male	85	14	Redacted
CARE_CURR_TA	Age/sex: 25-49 Male	1,400	815	Redacted
CARE_CURR_TA	Age/sex: 50+ Male	277	23	Redacted
CARE_CURR_TA	Age/sex: <1 Female	73	3	Redacted
CARE_CURR_TA	Age/sex: 1-4 Female	96	2	Redacted
CARE_CURR_TA	Age/sex: 5-9 Female	64	3	Redacted
CARE_CURR_TA	Age/sex: 10-14 Female	65	1	Redacted
CARE_CURR_TA	Age/sex: 15-19 Female	100	14	Redacted



CARE_CURR_TA	Age/sex: 20-24 Female	415	80	Redacted
CARE_CURR_TA	Age/sex: 25-49 Female	1,979	215	Redacted
CARE_CURR_TA	Age/sex: 50+ Female	277	29	Redacted
CARE_CURR_TA	Sum of Age/Sex disaggregates	5,038	1,199	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	163	0	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,504	75	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	250	2	Redacted
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	3,121	104	Redacted
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	5,038	181	Redacted
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	5,303	8,580	Redacted
CARE_NEW_DSD	Age/sex: <1 Male	56	32	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Male	90	76	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Male	65	57	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Male	50	108	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Male	30	29	Redacted
CARE_NEW_DSD	Age/sex: 20-24 Male	97	212	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Male	1,567	2,215	Redacted
CARE_NEW_DSD	Age/sex: 50+ Male	310	303	Redacted
CARE_NEW_DSD	Age/sex: <1 Female	56	32	Redacted
CARE_NEW_DSD	Age/sex: 1-4 Female	85	74	Redacted
CARE_NEW_DSD	Age/sex: 5-9 Female	53	46	Redacted
CARE_NEW_DSD	Age/sex: 10-14 Female	52	50	Redacted
CARE_NEW_DSD	Age/sex: 15-19 Female	107	366	Redacted

CARE_NEW_DSD	Age/sex: 20-24 Female	412	1,432	Redacted
CARE_NEW_DSD	Age/sex: 25-49 Female	1,978	3,089	Redacted
CARE_NEW_DSD	Age/sex: 50+ Female	295	459	Redacted
CARE_NEW_DSD	Sum of Age/sex disaggregates	5,303	8,580	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	85	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	714	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	82	0	Redacted
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	4,422	0	Redacted
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	5,303	0	Redacted
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	5,303	0	Redacted
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,719	3,430	Redacted
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,832		Redacted
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,347	3,127	Redacted
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	372	303	Redacted
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,719	3,430	Redacted
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	149		Redacted
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	30,572	41,208	Redacted
TX_CURR_DSD	Age/Sex: <1 Male	284	32	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Male	409	293	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Male	520	888	Redacted
TX_CURR_DSD	Age/Sex: 15+ Male	10,233		Redacted

TX_CURR_DSD	Age/Sex: <1 Female	353	35	Redacted
TX_CURR_DSD	Age/Sex: 1-4 Female	461	390	Redacted
TX_CURR_DSD	Age/Sex: 5-14 Female	618	978	Redacted
TX_CURR_DSD	Age/Sex: 15+ Female	17,694		Redacted
TX_CURR_DSD	Sum of age/sex disaggregates	2,645	41,208	Redacted
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0		Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	284	1	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	353	0	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,212		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	10,233	188	Redacted
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,432		Redacted
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	17,695	151	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,644		Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	27,928	339	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	30,572	339	Redacted
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	637	16	Redacted
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,800	307	Redacted
TX_CURR_TA	Age/Sex: <1 Male	89	0	Redacted
TX_CURR_TA	Age/Sex: 1-4 Male	61	0	Redacted
TX_CURR_TA	Age/Sex: 5-14 Male	52	0	Redacted
TX_CURR_TA	Age/Sex: 15+ Male	1,201		Redacted
TX_CURR_TA	Age/Sex: <1 Female	142	4	Redacted
TX_CURR_TA	Age/Sex: 1-4 Female	78	2	Redacted
TX_CURR_TA	Age/Sex: 5-14 Female	76	8	Redacted

TX_CURR_TA	Age/Sex: 15+ Female	3,101		Redacted
TX_CURR_TA	Sum of Age/Sex disaggregations	498	307	Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Male	94		Redacted
TX_CURR_TA	Aggregated Age/Sex: <1 Female	170		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Male	220		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Male	1,618		Redacted
TX_CURR_TA	Aggregated Age/Sex: <15 Female	353		Redacted
TX_CURR_TA	Aggregated Age/Sex: 15+ Female	2,609		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex <15	573		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex 15+	4,227		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,800		Redacted
TX_CURR_TA	Sum of Aggregated Age/Sex (<1 and 1-14) <15	264		Redacted
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,735	7,919	Redacted
TX_NEW_DSD	By Age/Sex: <1 Male	47	34	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Male	69	83	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Male	55	61	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Male	47	120	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Male	18	33	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Male	82	213	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,332	2,056	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Male	268	269	Redacted
TX_NEW_DSD	By Age/Sex: <1 Female	63	33	Redacted
TX_NEW_DSD	By Age/Sex: 1-4 Female	86	81	Redacted
TX_NEW_DSD	By Age/Sex: 5-9 Female	56	47	Redacted
TX_NEW_DSD	By Age/Sex: 10-14 Female	57	52	Redacted
TX_NEW_DSD	By Age/Sex: 15-19 Female	93	327	Redacted
TX_NEW_DSD	By Age/Sex: 20-24 Female	375	1,294	Redacted
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,834	2,803	Redacted
TX_NEW_DSD	By Age/Sex: 50+ Female	253	413	Redacted

TX_NEW_DSD	Sum of Age/Sex disaggregates	4,735	7,919	Redacted
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	12	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	166		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	2,011	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	20	0	Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	238		Redacted
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,320	0	Redacted
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,735	0	Redacted
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,739	3,653	Redacted
TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	4,203	4,001	Redacted
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	211		Redacted
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	160		Redacted
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,368		Redacted

TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	238		Redacted
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	180		Redacted
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,785		Redacted
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	296		Redacted
TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,444		Redacted
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	333		Redacted

TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,870		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	297		Redacted
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	396		Redacted
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	44	117	Redacted
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	44	117	Redacted
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	40,251	39,180	Redacted
TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	33,751	44,036	Redacted
TB_SCREEN_DSD	Age: <1	788	63	Redacted

TB_SCREEN_DSD	Age: 1-4	1,075	541	Redacted
TB_SCREEN_DSD	Age: 5-9	738	906	Redacted
TB_SCREEN_DSD	Age: 10-14	669	986	Redacted
TB_SCREEN_DSD	Age: 15-19	962	866	Redacted
TB_SCREEN_DSD	Age: 20-24	4,092		Redacted
TB_SCREEN_DSD	Age: 25-49	27,435		Redacted
TB_SCREEN_DSD	Age: 50+	4,492		Redacted
TB_SCREEN_DSD	Sum of Age disaggregates	4,232	39,180	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	3,271	242	Redacted
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	36,980	3,564	Redacted
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	40,251	3,806	Redacted
TB_SCREEN_DSD	Sex: Male	15,081	14,501	Redacted
TB_SCREEN_DSD	Sex: Female	25,170	24,679	Redacted
TB_SCREEN_DSD	Sum of Sex disaggregates	40,251	39,180	Redacted
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	5,038	1,579	Redacted

Implementing Mechanism Details

Mechanism ID: 17464	Mechanism Name: PACT II
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Pact	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 3,175,650	
Applied Pipeline Amount: 0	



Funding Source	Funding Amount
GHP-State	3,174,650
GHP-USAID	1,000

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: GBV	100,000
Focus Area:	GBV Prevention
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	150,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Implementation
Sub Area:	Capacity building
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Implementation
Sub Area:	Capacity building
Education	200,000
Condom programming	150,000
Economic Strengthening	200,000

Key Issues

(No data provided.)

Budget Code Information



Mechanism ID: 17464			
Mechanism Name: PACT II			
Prime Partner Name: Pact			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	95,087	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HKID	2,559,009	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HLAB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	318,333	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	203,221	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PP_PREV_DSD	Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period.	10,000	36,197
PP_PREV_DSD	Age/sex: 10-14 Male	1,200	0
PP_PREV_DSD	Age/sex: 15-19 Male	1,800	0
PP_PREV_DSD	Age/sex: 20-24 Male	0	0
PP_PREV_DSD	Age/sex: 25-49 Male	0	0
PP_PREV_DSD	Age/sex: 50+ Male	0	0
PP_PREV_DSD	Age/sex: 10-14 Female	2,800	13,711

PP_PREV_DSD	Age/sex: 15-19 Female	4,200	14,723
PP_PREV_DSD	Age/sex: 20-24 Female	0	7,763
PP_PREV_DSD	Age/sex: 25-49 Female	0	0
PP_PREV_DSD	Age/sex: 50+ Female	0	0
PP_PREV_DSD	Sum of Age/Sex disaggregates	10,000	36,197
OVC_ACC_DSD	Number of active beneficiaries receiving support from PEPFAR OVC programs to access HIV services	721	9,000
OVC_ACC_DSD	Sex: Male	372	
OVC_ACC_DSD	Sex: Female	349	
OVC_ACC_DSD	Sum of Sex disaggregates	721	
OVC_ACC_DSD	Age: <1	0	
OVC_ACC_DSD	Age: 1-4	0	
OVC_ACC_DSD	Age: 5-9	31	
OVC_ACC_DSD	Age: 10-14	136	
OVC_ACC_DSD	Age: 15-17	334	
OVC_ACC_DSD	Age: 18+	220	
OVC_ACC_DSD	Sum of Age disaggregates	721	
OVC_SERV_DSD	Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS	10,000	41,874
OVC_SERV_DSD	Sex: Male	3,000	
OVC_SERV_DSD	Sex: Female	7,000	
OVC_SERV_DSD	Sum of Sex disaggregates	10,000	
OVC_SERV_DSD	Age: <1	0	
OVC_SERV_DSD	Age: 1-4	0	
OVC_SERV_DSD	Age: 5-9	0	
OVC_SERV_DSD	Age: 10-14	4,000	
OVC_SERV_DSD	Age: 15-17	5,000	
OVC_SERV_DSD	Age: 18+	1,000	
OVC_SERV_DSD	Sum of Age disaggregates	10,000	

Implementing Mechanism Details



Mechanism ID: 17465	Mechanism Name: AIDSFree
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: John Snow, Inc.	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 5,526,824	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	5,526,824

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Human Resources for Health	150,000
Food and Nutrition: Policy, Tools, and Service Delivery	200,000
Gender: GBV	75,000
Focus Area:	Post GBV Care
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Sub Area:	Capacity building
Gender: Gender Equality	100,000
Focus Area:	Increase gender-equitable access to income and productive resources, including education
Sub Area:	Collection and Use of Gender-related Strategic Information



Sub Area:	Capacity building
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Sub Area:	Implementation
Motor Vehicles: Purchased	290,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17465		
Mechanism Name:	AIDSFree		
Prime Partner Name:	John Snow, Inc.		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	405,851	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	149,680	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	225,586	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	93,544	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	130,989	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Treatment	HTXS	4,266,083	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	255,091	0

Implementing Mechanism Indicator Information

Indicator Number	Label	2015	2016
PMTCT_ARV_TA	Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery	3,450	1,535
PMTCT_ARV_TA	Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry)	3,832	1,678
PMTCT_ARV_TA	Life-long ART (including Option B+)	2,474	
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy	1,497	669
PMTCT_ARV_TA	Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy	977	866
PMTCT_ARV_TA	Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period)	0	0
PMTCT_ARV_TA	Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery)	0	0
PMTCT_ARV_TA	Single-dose nevirapine (with or without tail)	0	0
PMTCT_ARV_TA	Sum of Regimen Type disaggregates	2,474	0
PMTCT_ARV_TA	Sum of New and Current disaggregates	2,474	1,535
PMTCT_STAT_TA	Number of pregnant women with known HIV status (includes women who were tested for	13,373	4,872

	HIV and received their results)		
PMTCT_STAT_TA	Number of new ANC and L&D clients	13,590	5,122
PMTCT_STAT_TA	By: Known positives at entry	2,675	1,237
PMTCT_STAT_TA	By: Number of new positives identified	2,363	443
PMTCT_STAT_TA	Sum of Positives Status disaggregates	5,038	1,680
HTC_TST_TA	Number of individuals who received T&C services for HIV and received their test results during the past 12 months	37,578	1,933
HTC_TST_TA	By Test Result: Negative	30,893	1,594
HTC_TST_TA	By Test Result: Positive	6,685	339
HTC_TST_TA	Sum of Test Result disaggregates	37,578	1,933
HTC_TST_TA	Age/sex: <1 Male	338	
HTC_TST_TA	Age/sex: 1-4 Male	1,061	
HTC_TST_TA	Age/sex: 5-9 Male	381	
HTC_TST_TA	Age/sex: 10-14 Male	206	
HTC_TST_TA	Age/sex: 15-19 Male	505	
HTC_TST_TA	Age/sex: 20-24 Male	1,388	
HTC_TST_TA	Age/sex: 25-49 Male	4,048	
HTC_TST_TA	Age/sex: 50+ Male	1,282	
HTC_TST_TA	Age/sex: <1 Female	442	
HTC_TST_TA	Age/sex: 1-4 Female	1,393	
HTC_TST_TA	Age/sex: 5-9 Female	493	
HTC_TST_TA	Age/sex: 10-14 Female	361	
HTC_TST_TA	Age/sex: 15-19 Female	3,776	
HTC_TST_TA	Age/sex: 20-24 Female	7,329	
HTC_TST_TA	Age/sex: 25-49 Female	11,723	
HTC_TST_TA	Age/sex: 50+ Female	2,852	
HTC_TST_TA	Sum of Age/Sex disaggregates	37,578	
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,986	125
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	7,223	360

HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	2,688	157
HTC_TST_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	25,681	1,291
HTC_TST_TA	Sum of Aggregated Age/Sex <15	4,674	282
HTC_TST_TA	Sum of Aggregated Age/Sex 15+	32,904	1,651
HTC_TST_TA	Sum of Aggregated Age/Sex disaggregates	37,578	1,933
CARE_CURR_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,376	48,318
CARE_CURR_DSD	Age/sex: <1 Male	266	54
CARE_CURR_DSD	Age/sex: 1-4 Male	383	312
CARE_CURR_DSD	Age/sex: 5-9 Male	275	371
CARE_CURR_DSD	Age/sex: 10-14 Male	212	393
CARE_CURR_DSD	Age/sex: 15-19 Male	100	235
CARE_CURR_DSD	Age/sex: 20-24 Male	487	664
CARE_CURR_DSD	Age/sex: 25-49 Male	8,061	11,632
CARE_CURR_DSD	Age/sex: 50+ Male	1,599	2,817
CARE_CURR_DSD	Age/sex: <1 Female	328	48
CARE_CURR_DSD	Age/sex: 1-4 Female	429	348
CARE_CURR_DSD	Age/sex: 5-9 Female	283	365
CARE_CURR_DSD	Age/sex: 10-14 Female	292	387
CARE_CURR_DSD	Age/sex: 15-19 Female	637	1,414
CARE_CURR_DSD	Age/sex: 20-24 Female	2,645	5,015
CARE_CURR_DSD	Age/sex: 25-49 Female	12,611	20,456
CARE_CURR_DSD	Age/sex: 50+ Female	1,768	3,807
CARE_CURR_DSD	Sun of Age/Sex disaggregates	30,376	48,318
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	1,136	1,130
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	10,247	15,347

CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	1,332	1,147
CARE_CURR_DSD	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	17,661	30,694
CARE_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	30,376	48,318
CARE_CURR_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,535	668
CARE_CURR_TA	Age/sex: <1 Male	40	0
CARE_CURR_TA	Age/sex: 1-4 Male	58	2
CARE_CURR_TA	Age/sex: 5-9 Male	42	1
CARE_CURR_TA	Age/sex: 10-14 Male	32	0
CARE_CURR_TA	Age/sex: 15-19 Male	16	0
CARE_CURR_TA	Age/sex: 20-24 Male	76	32
CARE_CURR_TA	Age/sex: 25-49 Male	1,260	293
CARE_CURR_TA	Age/sex: 50+ Male	250	16
CARE_CURR_TA	Age/sex: <1 Female	66	0
CARE_CURR_TA	Age/sex: 1-4 Female	86	4
CARE_CURR_TA	Age/sex: 5-9 Female	57	2
CARE_CURR_TA	Age/sex: 10-14 Female	59	1
CARE_CURR_TA	Age/sex: 15-19 Female	90	22
CARE_CURR_TA	Age/sex: 20-24 Female	373	79
CARE_CURR_TA	Age/sex: 25-49 Female	1,780	202
CARE_CURR_TA	Age/sex: 50+ Female	250	14
CARE_CURR_TA	Sum of Age/Sex disaggregates	4,535	668
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male	147	3
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male	1,354	341
CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female	225	7

CARE_CURR_TA	Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female	2,809	317
CARE_CURR_TA	Sum of Aggregated Age/Sex disaggregates	4,535	668
CARE_NEW_DSD	Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load	4,773	3,388
CARE_NEW_DSD	Age/sex: <1 Male	50	5
CARE_NEW_DSD	Age/sex: 1-4 Male	81	25
CARE_NEW_DSD	Age/sex: 5-9 Male	59	21
CARE_NEW_DSD	Age/sex: 10-14 Male	45	22
CARE_NEW_DSD	Age/sex: 15-19 Male	27	8
CARE_NEW_DSD	Age/sex: 20-24 Male	88	79
CARE_NEW_DSD	Age/sex: 25-49 Male	1,410	777
CARE_NEW_DSD	Age/sex: 50+ Male	279	141
CARE_NEW_DSD	Age/sex: <1 Female	50	5
CARE_NEW_DSD	Age/sex: 1-4 Female	77	23
CARE_NEW_DSD	Age/sex: 5-9 Female	48	16
CARE_NEW_DSD	Age/sex: 10-14 Female	47	18
CARE_NEW_DSD	Age/sex: 15-19 Female	97	162
CARE_NEW_DSD	Age/sex: 20-24 Female	370	579
CARE_NEW_DSD	Age/sex: 25-49 Female	1,780	1,243
CARE_NEW_DSD	Age/sex: 50+ Female	265	264
CARE_NEW_DSD	Sum of Age/sex disaggregates	4,773	3,388
CARE_NEW_DSD	Aggregated Age/sex: <15 Male	77	73
CARE_NEW_DSD	Aggregated Age/sex: 15+ Male	643	1,005
CARE_NEW_DSD	Aggregated Age/sex: <15 Female	73	63
CARE_NEW_DSD	Aggregated Age/sex: 15+ Female	3,980	2,247
CARE_NEW_DSD	Sum of Aggregated Age/sex disaggregates	4,773	3,388
CARE_NEW_TA	Sum of Aggregated Age/sex disaggregates	4,773	3,388
FN_THER_DSD	Number of clinically malnourished PLHIV who	70	

	received therapeutic and/or supplementary food during the reporting period.		
FN_THER_DSD	Number of PLHIV who were nutritionally assessed and found to be clinically undernourished.	70	
FN_THER_DSD	Age: <1	0	
FN_THER_DSD	Age: 1-4	2	
FN_THER_DSD	Age: 5-14	10	
FN_THER_DSD	Age: 15-17	12	
FN_THER_DSD	Age: 18+	46	
FN_THER_DSD	Sum of Age disaggregates	70	
FN_THER_DSD	Aggregated Age: <18	24	
FN_THER_DSD	Aggregated Age: 18+	46	
FN_THER_DSD	Sum of Aggregated Age disaggregates	70	
PMTCT_EID_DSD	Number of infants who had a virologic HIV test within 12 months of birth during the reporting period	3,719	2,915
PMTCT_EID_DSD	Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT)	3,832	
PMTCT_EID_DSD	By infants who received a virologic test within 2 months of birth	3,347	2,619
PMTCT_EID_DSD	By infants who received their first virologic HIV test between 2 and 12 months of age	372	296
PMTCT_EID_DSD	Sum of Infant Age disaggregates	3,719	2,915
PMTCT_EID_DSD	By infants with a positive virologic test result within 12 months of birth	149	
TX_CURR_DSD	Number of adults and children receiving antiretroviral therapy (ART)	28,279	42,084
TX_CURR_DSD	Age/Sex: <1 Male	262	38
TX_CURR_DSD	Age/Sex: 1-4 Male	378	259
TX_CURR_DSD	Age/Sex: 5-14 Male	481	691

TX_CURR_DSD	Age/Sex: 15+ Male	9,466	
TX_CURR_DSD	Age/Sex: <1 Female	326	36
TX_CURR_DSD	Age/Sex: 1-4 Female	427	297
TX_CURR_DSD	Age/Sex: 5-14 Female	572	697
TX_CURR_DSD	Age/Sex: 15+ Female	16,367	
TX_CURR_DSD	Sum of age/sex disaggregates	2,446	42,084
TX_CURR_DSD	Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	
TX_CURR_DSD	Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT]	0	
TX_CURR_DSD	Aggregated Age/Sex: <1 Male	262	38
TX_CURR_DSD	Aggregated Age/Sex: <1 Female	326	36
TX_CURR_DSD	Aggregated Age/Sex: <15 Male	1,121	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Male	9,466	13,490
TX_CURR_DSD	Aggregated Age/Sex: <15 Female	1,325	
TX_CURR_DSD	Aggregated Age/Sex: 15+ Female	16,367	26,576
TX_CURR_DSD	Sum of Aggregated Age/Sex <15	2,446	
TX_CURR_DSD	Sum of Aggregated Age/Sex 15+	25,833	40,066
TX_CURR_DSD	Sum of Aggregated Age/Sex disaggregates	28,279	40,066
TX_CURR_DSD	Sum of Aggregated Age/Sex (<1 and 1-14) <15	588	2,018
TX_CURR_TA	Number of adults and children receiving antiretroviral therapy (ART)	4,440	515
TX_CURR_TA	Age/Sex: <1 Male	83	0
TX_CURR_TA	Age/Sex: 1-4 Male	57	1
TX_CURR_TA	Age/Sex: 5-14 Male	48	1
TX_CURR_TA	Age/Sex: 15+ Male	1,111	
TX_CURR_TA	Age/Sex: <1 Female	131	0
TX_CURR_TA	Age/Sex: 1-4 Female	72	2
TX_CURR_TA	Age/Sex: 5-14 Female	70	2
TX_CURR_TA	Age/Sex: 15+ Female	2,868	

TX_CURR_TA	Sum of Age/Sex disaggregations	461	515
TX_NEW_DSD	Number of adults and children newly enrolled on antiretroviral therapy (ART)	4,380	5,561
TX_NEW_DSD	By Age/Sex: <1 Male	44	6
TX_NEW_DSD	By Age/Sex: 1-4 Male	64	43
TX_NEW_DSD	By Age/Sex: 5-9 Male	51	30
TX_NEW_DSD	By Age/Sex: 10-14 Male	43	32
TX_NEW_DSD	By Age/Sex: 15-19 Male	17	13
TX_NEW_DSD	By Age/Sex: 20-24 Male	76	122
TX_NEW_DSD	By Age/Sex: 25-49 Male	1,233	1,315
TX_NEW_DSD	By Age/Sex: 50+ Male	248	206
TX_NEW_DSD	By Age/Sex: <1 Female	59	6
TX_NEW_DSD	By Age/Sex: 1-4 Female	79	41
TX_NEW_DSD	By Age/Sex: 5-9 Female	52	24
TX_NEW_DSD	By Age/Sex: 10-14 Female	53	27
TX_NEW_DSD	By Age/Sex: 15-19 Female	86	267
TX_NEW_DSD	By Age/Sex: 20-24 Female	347	967
TX_NEW_DSD	By Age/Sex: 25-49 Female	1,694	2,080
TX_NEW_DSD	By Age/Sex: 50+ Female	234	381
TX_NEW_DSD	Sum of Age/Sex disaggregates	4,380	5,560
TX_NEW_DSD	Aggregated Grouping by Age: <1 Male	11	5
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Male	153	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Male	1,860	1,656
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <1 Female	18	4
TX_NEW_DSD	Aggregated Grouping by Age/Sex: <15 Female	221	
TX_NEW_DSD	Aggregated Grouping by Age/Sex: 15+ Female	2,146	3,691
TX_NEW_DSD	Sum of Aggregated Age/Sex disaggregates	4,380	5,347
TX_RET_DSD	Number of adults and children who are still alive and on treatment at 12 months after initiating ART	3,459	4,292

TX_RET_DSD	Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up	3,888	4,928
TX_RET_DSD	Age: 0-4 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	195	
TX_RET_DSD	Age: 5-14 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	148	
TX_RET_DSD	Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,115	
TX_RET_DSD	Age: 0-4 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	220	
TX_RET_DSD	Age: 5-14 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	166	
TX_RET_DSD	Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,501	
TX_RET_DSD	Aggregated Age: <15 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	273	

TX_RET_DSD	Aggregated Age: 15+ (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	3,185	
TX_RET_DSD	Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	308	
TX_RET_DSD	Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	3,580	
TX_RET_DSD	Pregnancy and breastfeeding status (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)	275	
TX_RET_DSD	Pregnancy and breastfeeding status (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)	366	
FPINT_SITE_DSD	Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services	26	
FPINT_SITE_DSD	Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment	26	
TB_SCREEN_DSD	The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period	32,907	42,563



TB_SCREEN_DSD	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	30,376	48,318
TB_SCREEN_DSD	Age: <1	580	75
TB_SCREEN_DSD	Age: 1-4	791	590
TB_SCREEN_DSD	Age: 5-9	543	979
TB_SCREEN_DSD	Age: 10-14	493	1,066
TB_SCREEN_DSD	Age: 15-19	707	942
TB_SCREEN_DSD	Age: 20-24	3,011	
TB_SCREEN_DSD	Age: 25-49	20,188	
TB_SCREEN_DSD	Age: 50+	3,306	
TB_SCREEN_DSD	Sum of Age disaggregates	3,114	42,563
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: <15	2,407	2,712
TB_SCREEN_DSD	Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+	27,212	39,851
TB_SCREEN_DSD	Sum of Aggregated Age disaggregates	29,619	42,563
TB_SCREEN_DSD	Sex: Male	11,097	14,902
TB_SCREEN_DSD	Sex: Female	18,522	27,660
TB_SCREEN_DSD	Sum of Sex disaggregates	29,619	42,562
TB_SCREEN_TA	Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load	4,535	668

Implementing Mechanism Details

Mechanism ID: 17548	Mechanism Name: Supply Chain Management System (SCMS)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Partnership for Supply Chain Management	
Agreement Start Date: Redacted	Agreement End Date: Redacted



TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 7,083,174	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	3,540,092
GHP-USAID	3,543,082

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17548			
Mechanism Name: Supply Chain Management System (SCMS)			
Prime Partner Name: Partnership for Supply Chain Management			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	7,083,174	0

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

Mechanism ID: 17555	Mechanism Name: USDF MeHIN
Funding Agency: DOD	Procurement Type: Grant
Prime Partner Name: VISTA PARTNERS	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 26,831	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	26,831

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17555		
Mechanism Name:	USDF MeHIN		
Prime Partner Name:	VISTA PARTNERS		
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	26,831	0
------------------------	------	--------	---

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17559	Mechanism Name: RPSO-Supported Renovation Projects in Swaziland MOH Facilities
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Regional Procurement Support Office/Frankfurt	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)



Budget Code Information

Mechanism ID:	17559		
Mechanism Name:	RPSO-Supported Renovation Projects in Swaziland MOH Facilities		
Prime Partner Name:	Regional Procurement Support Office/Frankfurt		
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXD	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17572	Mechanism Name: TA Support for the Strengthening of Blood Transfusion
Funding Agency: HHS/CDC	Procurement Type: Cooperative Agreement
Prime Partner Name: American Association of Blood Banks	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 85,000	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	85,000



Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17572			
Mechanism Name: TA Support for the Strenghtening of Blood Transfusion			
Prime Partner Name: American Association of Blood Banks			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HMBL	85,000	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17775	Mechanism Name: Building Local Capacity (BLC)
Funding Agency: USAID	Procurement Type: Contract
Prime Partner Name: Management Sciences for Health	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: No
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:



Total All Funding Sources: 0	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	0

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

(No data provided.)

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17775			
Mechanism Name: Building Local Capacity (BLC)			
Prime Partner Name: Management Sciences for Health			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HVTB	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	PDCS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount



Governance and Systems	HVSI	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	CIRC	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	MTCT	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	0	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	PDTX	0	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17965	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17966	Mechanism Name: Support for International Family Planning and Health Organization 2
Funding Agency: USAID	Procurement Type: Contract



Prime Partner Name: Population Services International	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 645,742	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	645,742

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	80,000
Focus Area:	Equity in HIV prevention, care, treatment and support
Sub Area:	Collection and Use of Gender-related Strategic Information
Condom programming	500,000

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID:	17966
Mechanism Name:	Support for International Family Planning and Health Organization 2
Prime Partner Name:	Population Services International



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	161,004	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Prevention	HVOP	484,738	0

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Mechanism ID: 17967	TBD: Yes
REDACTED	

Implementing Mechanism Details

Mechanism ID: 17972	Mechanism Name: Measure Evaluation (IHM)
Funding Agency: USAID	Procurement Type: Cooperative Agreement
Prime Partner Name: Measure Evaluation	
Agreement Start Date: Redacted	Agreement End Date: Redacted
TBD: No	New Mechanism: Yes
Global Fund / Multilateral Engagement: N/A	
G2G: No	Managing Agency:

Total All Funding Sources: 936,169	
Applied Pipeline Amount: 0	
Funding Source	Funding Amount
GHP-State	936,169

Sub Partner Name(s)

(No data provided.)

Cross-Cutting Budget Attribution(s)

Gender: Gender Equality	150,000
Focus Area:	Changing harmful gender norms and promoting positive gender norms
Sub Area:	Collection and Use of Gender-related Strategic Information
Focus Area:	Equity in HIV prevention, care, treatment and support
Gender: GBV	50,000
Focus Area:	Post GBV Care
Sub Area:	Monitoring and Evaluation

Key Issues

(No data provided.)

Budget Code Information

Mechanism ID: 17972			
Mechanism Name: Measure Evaluation (IHM)			
Prime Partner Name: Measure Evaluation			
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Care	HBHC	200,000	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	HVSI	373,169	0
Strategic Area	Budget Code	Planned Amount	On Hold Amount
Governance and Systems	OHSS	163,000	0



Strategic Area	Budget Code	Planned Amount	On Hold Amount
Treatment	HTXS	200,000	0

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business
U.S. Agency for International Development

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Computers/IT Services			95,056	95,056	41,044
ICASS			591,060	591,060	120,778
Institutional Contractors			86,400	86,400	0
Management Meetings/Professional Development			0	0	10,555
Staff Program Travel			71,581	71,581	17,200
USG Staff Salaries and Benefits			889,868	889,868	421,253
Total	0	0	1,733,965	1,733,965	610,830

U.S. Department of Defense

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		15,071		15,071	5,218
ICASS		21,737		21,737	18,263
Management Meetings/Professional Development		4,391		4,391	2,609



Non-ICASS Administrative Costs		2,783		2,783	5,217
Staff Program Travel		10,173		10,173	7,827
USG Staff Salaries and Benefits		36,647		36,647	33,470
Total	0	90,802	0	90,802	72,604

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		124,869		124,869	35,333
Computers/IT Services		92,648		92,648	14,133
ICASS		428,666		428,666	141,334
Institutional Contractors		417,724		417,724	0
Management Meetings/Professio nal Development		21,540		21,540	16,440
Non-ICASS Administrative Costs		36,029		36,029	26,388
Staff Program Travel	0	61,566		61,566	22,459
USG Staff Salaries and Benefits	487,500	293,144		780,644	318,836
Total	487,500	1,476,186	0	1,963,686	574,923



U.S. Department of State

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Capital Security Cost Sharing		25,000		25,000	65,000
Computers/IT Services		0		0	2,000
ICASS		70,000		70,000	160,000
Management Meetings/Professional Development		0		0	3,000
Non-ICASS Administrative Costs		20,000		20,000	3,600
Staff Program Travel		5,000		5,000	7,000
USG Staff Salaries and Benefits		0		0	188,345
Total	0	120,000	0	120,000	428,945

U.S. Peace Corps

Agency Cost of Doing Business	GAP	GHP-State	GHP-USAID	Cost of Doing Business Category Total	Applied Pipeline
Non-ICASS Administrative Costs		252,012		252,012	0
Peace Corps Volunteer Costs		743,333		743,333	0



Staff Program Travel		4,100		4,100	0
USG Staff Salaries and Benefits		0		0	0
Total	0	999,445	0	999,445	0